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For decades laboratory diagnostics of dyslipidemia has been based on serum 
total cholesterol, HDL-cholesterol, triglycerides and calculated or direct LDL-
cholesterol measurements. These cardiovascular lipid risk factors have been 
measured in population-based FINRISK health surveys during the last four 
decades in Finland. Participation in different external quality assessment 
programs with target lipid values measured by reference methods has made 
it possible to assess accurately population trends. However, even the accurate 
measurements of the cholesterol content inside lipoprotein particles do not tell 
everything about the risk for the cardiovascular disease (CVD). 
Apolipoprotein A-I (apoA-I) is the main protein component in high-density 
lipoproteins (HDL) and apoB is the main protein in all other atherogenic 
lipoprotein particles. An increased number of apoB-containing lipoproteins but 
a normal or even low LDL-cholesterol is a common feature in obesity, metabolic 
syndrome and type 2 diabetes. Therefore apoA-I and apoB measurements 
could produce more specific information for the early risk assessment of CVD 
compared to the direct measurements of HDL- and LDL-cholesterol.
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Abstract 
Jaana Leiviskä. Diagnostics of Dyslipidemia – From Cholesterol to Apolipoproteins. 
National Institute for Health and Welfare (THL). Research 101. 120 pages. 
Helsinki, Finland 2013. 
ISBN 978-952-245-854-4 (printed); ISBN 978-952-245-855-1 (online publication) 
 
For decades cholesterol and low-density lipoprotein cholesterol (LDL-C) have been 
the cornerstones of cardiovascular risk assessment. The increasing prevalences in 
obesity, metabolic syndrome, and type 2 diabetes have challenged the diagnostics of 
dyslipidemia due to changed serum lipoprotein composition. The atherogenic 
dyslipidemia consists of decreased high-density lipoprotein cholesterol (HDL-C), 
increased triglycerides and small, dense low-density lipoprotein (sd-LDL) with 
increased number of apolipoprotein B (apoB) particles in serum.  Apolipoprotein A-
I (apoA-I) is the main apolipoprotein of HDL particles and apoB is the main 
apolipoprotein in LDL, intermediate-density lipoproteins (IDL), very-low density 
lipoproteins (VLDL), lipoprotein(a) [(Lp(a)], and chylomicrons, respectively. The 
systematic errors in lipid and lipoprotein measurements may influence the accuracy 
of cardiovascular risk assessment and interpretations of population trends. 
The first aim of this study was to assess the systematic errors in cholesterol, 
triglycerides, and HDL-C measurements. Secondly, the effect of fasting and non-
fasting triglyceride values to the prevalences of high LDL-C and metabolic 
syndrome was estimated. The reference intervals for apoA-I, apoB, and apoB/apoA-
I ratio were calculated and they were compared with the traditional lipid and 
lipoprotein concentrations in different pathophysiological conditions. Finally, two 
direct HDL-C methods and two turbidimetric apoA-I methods in two independent 
laboratories were also compared to discover the concordance between these methods. 
The data for estimating accuracy of cholesterol, triglycerides, and HDL-C 
measurements was obtained from five different external quality assessment (EQA) 
programs, in which the Laboratory of Analytical Biochemistry at the National 
Institute for Health and Welfare has participated since 1978. The laboratory data for 
lipid and lipoprotein population trends was obtained from the FINRISK population-
based health surveys during 1982 – 2012. The fresh serum samples for HDL-C and 
apoA-I method comparisons (n=413) were collected in the occupational health care 
laboratory. 
The mean annual bias according to the EQAs for the cholesterol during 1978 – 
2004 was -0.7 % (95% CI -0.9 to -0.6). For triglycerides the mean annual bias 
during 1978 – 2007 was -1.5 % (95% CI -2.3 to -0.8) and for HDL-C during 1982 – 
2012 it was -2.3 % (95% CI -3.3 to -1.4).  
The method comparison of two direct HDL-C methods showed a concentration-
dependent difference between these methods. With low HDL-C concentrations (<1.0 
mmol/l) difference between methods was negative -12.0 % (95% CI -13.5 to -10.0), 
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but with higher concentrations (>1.5 mmol/l) turned to positive: 9.0 % (95% CI 7.0 
– 10.5). 
We calculated conversion factors for transforming non-fasting triglyceride 
concentrations to true-fasting values according to the data from FINRISK studies in 
1992, 1997, and 2002. The mean triglyceride concentration decreased 3.7 % for 
every fasting hour. Transforming non-fasting triglyceride values to true-fasting 
values increased the prevalence of high LDL-C (>3.0 mmol/l) from 51.3 % to 54.8 
% and the prevalence of metabolic syndrome decreased from 39.7 % to 37.6 % in 
FINRISK 2007 study.  
The reference intervals for apoA-I, apoB, and apoB/apoA-I ratio were calculated 
from FINRISK 2007 study. The therapeutic goal for apoB in both sexes was 0.9 g/l, 
which coincided with LDL-C concentration of 3.0 mmol/l. For apoA-I target values 
were >1.2 g/l in men and >1.4 g/l in women, which corresponded to HDL-C 
concentrations 1.0 mmol/l in men and 1.2 mmol/l in women. Obese men and women 
had the highest apoB concentrations and apoB/apoA-I ratios compared to the 
healthy reference group. Men with self-reported cardiovascular disease (CVD) or 
diabetes had lower apoB concentrations and apoB/apoA-I ratio than the averages in 
the healthy reference group, but on the contrary, in women apoB concentrations and 
apoB/apoA-I ratios were higher in groups with obesity, CVD, hypertension, or 
diabetes. 
Participating in the external quality assessment programs with target values 
measured by the reference methods was essential, when interpreting the effects of 
the systematic errors on the population trends. The concentration-dependent 
differences in homogeneous HDL-C methods may cause misclassificatios in the risk 
assessment of cardiovascular disease. However, apoA-I methods showed better 
agreement than HDL-C in the method comparisons. ApoB measurements may 
produce more specific information in the risk assessment for CVD, especially in 
obesity, metabolic syndrome, and type 2 diabetes than total cholesterol and LDL-C 
measurements. Finally, the presented data supports the idea to incorporate apoA-I 
and apoB measurements to the national guidelines for assessment and treatment of 
dyslipidemia. 
 
 
Keywords: dyslipidemia, cholesterol, triglycerides, HDL-C, LDL-C, apoA-I, apoB, 
systematic error, external quality assessment, homogeneous methods 
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Vuosikymmenten ajan seerumin kokonaiskolesterolin ja low-density lipoproteiini 
(LDL)-kolesterolin määritykset ovat olleet sydän- ja verisuonitautien riskin-
arvioinnin kulmakiviä. Ylipainon, metabolisen oireyhtymän ja tyypin 2 diabeteksen 
lisääntyminen suomalaisessa väestössä on muuttanut elimistön rasvaliukoisia 
yhdisteitä kuljettavien lipoproteiinien koostumusta, mikä on tuonut uusia haasteita 
dyslipidemioiden laboratoriodiagnostiikkaan. Aterogeenisessa dyslipidemiassa 
seerumin high-density lipoproteiini (HDL)-kolesterolin pitoisuus on alentunut, ja 
samanaikaisesti seerumin triglyseridipitoisuus sekä pienten, tiheiden LDL-
partikkeleiden ja apolipoproteiini B:n määrä (apoB) on koholla. Apolipoproteiini A-
I (apoA-I) on HDL-partikkeleiden tärkein apolipoproteiini ja apoB vastaavasti LDL-,
IDL- (intermediate-density lipoproteiini), VLDL- (very low-density lipoproteiini) 
ja lipoproteiini(a)- [Lp(a)] partikkeleiden sekä kylomikronien tärkein 
apolipoproteiini. Systemaattiset virheet lipidi- ja lipoproteiinimäärityksissä voivat 
vaikuttaa sydän- ja verisuonitautien riskinarvioinnin tarkkuuteen ja väestötason 
muutosten tulkintaan. 
Tutkimuksen tavoitteina oli arvioida systemaattisen virheen vaikutuksia 
kolesteroli-, triglyseridi- ja HDL-kolesterolimäärityksissä sekä paaston pituuden 
vaikutuksia triglyseridipitoisuuksiin ja korkean LDL-kolesterolin (> 3.0 mmol/l) ja 
metabolisen oireyhtymän esiintymiseen. Tavoitteena oli myös määrittää apoA-I:n, 
apoB:n ja apoB/apoA-I-suhteen viitearvot suomalaisessa väestössä ja verrata niitä 
kolesteroli-, LDL-kolesteroli-, HDL-kolesteroli- ja triglyseridipitoisuuksiin eri 
tautiryhmissä. Lopuksi verrattiin kahta suoraa HDL-kolesterolimenetelmää ja kahta 
immunoturbidimetristä apoA-I-menetelmää kahdessa eri laboratoriossa. 
Aineistona kolesteroli-, triglyseridi- ja HDL-kolesterolimenetelmien 
systemaattisen virheen arviointiin käytettiin Terveyden ja hyvinvoinnin laitoksen 
(THL) analyyttisen biokemian laboratorion (TLAB) viiden ulkoisen 
laadunarviointiohjelman tuloksia vuosilta 1978 – 2012. FINRISKI-tutkimusten 
lipidi- ja lipoproteiinituloksia vuosilta 1982 – 2012 käytettiin laboratoriotulosten 
systemaattisen virheen ja väestötasolla tapahtuneiden muutosten yhteisvaikutusten 
tulkinnassa. Kahden suoran HDL-kolesterolimenelmän ja apoA-I-menetelmän 
vertailussa käytettiin yksityisen työterveyshuollon laboratorion kautta saatuja 
tuoreita seeruminäytteitä (n=413). 
Keskimääräinen systemaattinen virhe kolesterolimäärityksissä ulkoisten 
laadunarviointikierrosten perusteella vuosina 1978 – 2004 oli -0.7 % (95 %:n 
luottamusväli -0.9, -0.6). Triglyseridimäärityksissä keskimääräinen systemaattinen 
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virhe vuosina 1978 – 2007 oli -1.5 % (-2.3, -0.8) ja HDL-kolesterolimäärityksissä 
vuosina 1982 – 2012 systemaattinen virhe oli -2.3 %       (-3.3, -1.4).  
Kahden suoran HDL-kolesterolimenetelmän vertailussa havaittiin konsentraatio-
riippuvainen ero: matalilla HDL-kolesterolipitoisuuksilla (<1.0 mmol/l) 
menetelmien välinen ero oli negatiivinen -12.0 % (-13.5, -10.0), mutta korkeammilla 
(>1.5 mmol/l) HDL-kolesterolipitoisuuksilla ero oli keskimäärin +9.0 % (7.0, 10.5).  
Jotta FINRISKI-tutkimuksissa käytettävän neljän tunnin paaston vaikutukset 
triglyseridipitoisuuksiin voitaisiin arvioida, kehitettiin muunnoskertoimet täydellisen 
paaston jälkeisen triglyseridipitoisuuden laskemiseksi vuosien 1992, 1997 ja 2002 
FINRISKI-tutkimusten triglyseriditulosten perusteella. Seerumin triglyseridi-
pitoisuus laski keskimäärin 3.7 prosentilla jokaisen paastotunnin aikana. 
Alkuperäisten triglyseridikonsentraatioiden muuntaminen paastoarvoiksi FINRISKI 
2007 -aineistossa nosti korkean LDL-kolesterolin (>3.0 mmol/l) esiintymisosuuden 
51.3 prosentista 54.8 prosenttiin. Metabolisen oireyhtymän esiintyminen FINRISKI 
2007 -aineistossa puolestaan väheni 39.7 prosentista 37.6 prosenttiin.  
ApoA-I:n, apoB:n ja apoB/apoA-I suhteen viitearvot laskettiin FINRISKI 2007 –
aineistosta. ApoB:n tavoitearvoksi määritettiin sekä miehille että naisille 0.9 g/l, 
joka vastasi LDL-kolesterolipitoisuutta 3.0 mmol/l. ApoA-I:n tavoitearvo miehille 
oli 1.2 g/l ja naisille 1.4 g/l. Lihavilla miehillä ja naisilla oli korkeimmat apoB- 
pitoisuudet ja korkeimmat apoB/apoA-I suhteet verrattuna terveeseen 
viitearvoaineistoon. Niillä miehillä, joilla oli todettu sydän- ja verisuonitauti tai 
diabetes, oli matalammat apoB-pitoisuudet ja apoB/apoA-I suhde kuin terveillä, 
mutta naisilla tilanne oli päinvastainen.   
Osallistuminen ulkoisen laadunarvioinnin kierroksiin, joissa käytetään 
referenssimenetelmiin jäljitettäviä tavoitearvoja, on välttämätöntä, jotta väestötason 
muutoksia pystytään tulkitsemaan oikein. Suorissa HDL-kolesterolimenetelmissä 
havaitut konsentraatiosta riippuvaiset tulostasoerot voivat aiheuttaa virheellisiä 
tulkintoja sydän- ja verisuonitautien riskinarvioinnissa. ApoA-I-menetelmissä 
vastaavaa eroa ei havaittu. ApoB:n määrityksellä voidaan saada tarkempaa tietoa 
sydän- ja verisuonitautiriskistä kuin kolesteroli- tai LDL-kolesterolimäärityksillä 
erityisesti ylipainoisilla, metabolista oireyhtymää sairastavilla tai tyypin 2 
diabeetikoilla. ApoA-I- ja apoB-määritykset olisikin syytä lisätä Dyslipidemioiden 
Käypä hoito –suositukseen. 
 
Avainsanat: Dyslipidemia, kolesteroli, triglyseridit, HDL-kolesteroli, LDL-
kolesteroli, apoA-I, apoB, systemaattinen virhe, ulkoinen laadunarviointi, 
kolesterolimääritykset 
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1 Introduction 
Cardiovascular disease (CVD) is still the leading cause for death in the developed 
countries and with globalized Western lifestyle these diseases are becoming more 
common also in the developing countries (Catapano et al. 2011). The basic risk 
factors for CVD are hypercholesterolemia, smoking, male gender, and hypertension, 
but increasing prevalences of obesity, metabolic syndrome (MetS), and type 2 
diabetes can multiply the risk. The National Cholesterol Education Program (NCEP) 
Adult Treatment Panel (ATP) III in the US and the European Society of Cardiology 
(ESC) together with the European Atherosclerosis Society (EAS) have developed 
guidelines for the risk assessment and treatment of cardiovascular disease (Grundy 
et al. 2004, Perk et al. 2012). Laboratory measurements to diagnose dyslipidemia – 
increased cholesterol, low-density lipoprotein cholesterol (LDL-C), or triglycerides 
concentrations, or decreased high-density lipoprotein cholesterol (HDL-C) 
concentration – have been a part of these guidelines since the beginning. The 
standardization and accuracy of analytical methods and the appropriate screening 
tools have been vital for the clinical laboratories to identify the relevant people in 
the risk. 
The latest guidelines are based on the use of LDL-C as a primary target of 
prevention and treatment for CVD. The secondary target is non-HDL-C especially 
for hypertriglyceridemic subjects. Hypertriglyceridemia is a common feature in 
obesity, MetS, and type 2 diabetes and it belongs also to the atherogenic 
dyslipidemia. The other components of atherogenic dyslipidemia are low HDL-C 
and an increased number of small, dense low-density lipoprotein (LDL) particles 
(sd-LDL) (Austin et al. 1990). The common nutritional background in this condition 
has revealed to be a low-fat but high-carbohydrate diet (Volek et al. 2008). The liver 
produces apolipoprotein B (apoB)-containing very low-density lipoprotein particles 
from the extra free fatty acids and carbohydrates after their change to triglycerides to 
deliver cholesterol and triglycerides to the extrahepatic tissues.  
Atherogenic lipoprotein particles consist of chylomicron remnants, very low-
density lipoproteins (VLDL), VLDL remnants, intermediate-density lipoproteins 
(IDL), low-density lipoproteins (LDL), and lipoprotein(a), Lp(a). Chylomicrons 
deliver lipids from the diet, but the other atherogenic lipoproteins are derived from 
the liver and metabolized from the VLDL particles. All these particles contain one 
nonexchangeable apoB molecule and different composition of free cholesterol, 
cholesterol esters, phospholipids, triglycerides and other apolipoproteins. The 
measurement of apoB is a better estimate of the atherogenic lipoprotein particles 
than LDL-C concentration, which varies according to the size of LDL (Contois et al. 
2009). The LDL-C concentration can be normal or even low in obesity, MetS, and 
Introduction 
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type 2 diabetes, resulting in the underestimation of CVD risk in these conditions 
(Sniderman et al. 2006). 
Recently, the specificity of direct HDL-C and LDL-C methods has been 
challenged (Miller et al. 2010).  HDL-C measurements are used to calculate LDL-C 
by the Friedewald formula and for non-HDL-C determination, which are the primary 
and the secondary targets for the prevention and treatment of CVD, respectively. 
The method-dependent differences in direct HDL-C and LDC-C measurements may 
impact on the accuracy of the risk assessment in the clinical practice.  
The first aim of this study was to assess the systematic errors in the serum 
cholesterol, triglyceride, and HDL-C measurements during four decades in the 
Laboratory of Analytical Biochemisty (TLAB) at the National Institute for Health 
and Welfare; and the second aim was to assess the effect of systematic error to the 
interpretations of population trends in the FINRISK health examination studies. The 
third aim was to compare the use of fasting and non-fasting triglyceride values in 
population studies and when calculating the prevalences of high LDL-C or MetS. 
We also compared two direct HDL-C methods and two turbidimetric apolipoprotein 
A-I (apoA-I) methods in two separate laboratories to discover the concordance 
between these methods. Furthermore, the reference intervals for apoA-I, apoB, and 
apoB/apoA-I ratio were calculated and these reference intervals were compared with 
values in different pathophysiological conditions in the FINRISK 2007 study.  
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2 Review of the literature 
2.1 Risk assessment of cardiovascular disease 
For decades total cholesterol and LDL-C have been the primary targets for 
prevention and treatment of cardiovascular disease, but in 1993 NCEP launched new 
guidelines in ATP II, which recommended the addition of HDL-C measurements 
with total cholesterol to screen coronary heart disease (CHD) (Summary of the 
second report of the National Cholesterol Education Program (NCEP) Expert Panel 
on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult 
Treatment Panel II 1993)). ATP III increased emphasis on the risk of high 
triglycerides by decreasing the cut-off value for normal triglycerides to 1.7 mmol/l 
and introduced non-HDL-C as a new secondary marker for hypertriglyceridemic 
patients (Expert Panel on Detection, Evaluation, and Treatment of High Blood 
Cholesterol in Adults 2001). In addition, a lower cut-off value for LDL-C (2.58 
mmol/l) was recommended as a treatment goal for people already having CHD. ATP 
III recommended also screening with the fasting lipid profile: total cholesterol, 
LDL-C, HDL-C, and triglycerides. NCEP ATP is working on the next report (ATP 
IV) with the aim to simplify the recommendations for clinical practice. According to 
the latest evidence, the ideal LDL-C target for the high-risk patients should be as 
low as 1.8 mmol/l and the use of non-HDL-C and apoB are recommended for the 
follow-up of drug treatment (Martin et al. 2012). 
 The Finnish treatment goals shown in Table 1 are based on the European 
guidelines on cardiovascular disease prevention by the European Society of 
Cardiology (Graham et al. 2007).  The Fifth Joint Task Force (JTF) of the European 
Societies on Cardiovascular Disease Prevention in Clinical Practice has updated the 
recommendations based on the latest scientific knowledge about cardiovascular 
disease risk assessment (Perk et al. 2012). Specific treatment goals for HDL-C have 
not been defined, but values under 1.0 mmol/l in men and 1.2 mmol/l in women 
increase risk for CVD. Treatment goal for triglycerides is the same <1.7 mmol/l as 
in the ATP III guidelines. According to these guidelines, apoB and apoB/apoA-I 
ratio do not add any further information to the CVD risk assessment, but they can be 
measured when available.   
 
 
 
 
 
Review of the literature 
 
THL — Research 101·2013 18 
Laboratory Diagnostics of 
Dyslipidemia 
 
 
Table 1. Treatment goals for cholesterol, LDL-C, triglycerides, and HDL-C in 
 Finland (Graham et al. 2007).  
Target Goal in normal population 
(mmol/l) 
Goal for high risk subjects 
(mmol/l) 
Cholesterol < 5.0 <4.0 – 4.5 
LDL-C <3.0 <2.0a – 2.5 
Triglycerides <2.0 <2.0 
HDL-C >1.0  >1.0  
a For the highest risk subjects LDL-C<1.8 mmol/l is recommended 
 
2.2 Lipids 
Lipids consist of the diverse groups of molecules, which are nearly insoluble in 
water, but soluble in organic solvents. The most important lipids in the human body 
are cholesterol and cholesterol esters, fatty acids, triglycerides, glycerophospholipids, 
sphingolipids, bile acids, steroid hormones, and fat-soluble vitamins. Lipids are 
structural components in biomembranes (glycerophospholipids, sphingolipids, and 
cholesterol); they function as hormones, precursors of hormones, signaling 
molecules, metabolic fuel (fatty acids), or energy storage (triglycerides), and aid in 
digestion of fat (bile acids) (Vance and Vance 2002). 
Cholesterol is an essential molecule for maintenance of membrane fluidity and 
permeability, and it serves as a precursor of bile acids, steroid hormones and vitamin 
D. Cholesterol homeostasis in the cells is maintained by the dietary absoption, de 
novo synthesis, metabolism to bile acids and sterol hormones, and excretion as bile 
acids (Hu et al. 2010). All human cells are capable of synthesizing cholesterol from 
acetate, which can be originated from the metabolism of carbohydrates or fats, but 
the liver and intestine are the main organs for de novo synthesis of cholesterol 
(Vance and Vance 2002, Blom et al. 2011). Dietary lipids and endogenous lipids 
synthesized by the liver and extrahepatic tissues are transported in the circulation 
with apolipoproteins as lipoprotein complexes (Grundy 2011).  
2.3 Lipoproteins 
The classification of lipoproteins has traditionally been based on the different 
density of lipoprotein particles separated by ultracentrifugation. The main classes of 
lipoproteins are chylomicrons, very low-density lipoproteins (VLDL), intermediate-
density lipoproteins (IDL), low-density lipoproteins (LDL), lipoprotein(a) [Lp(a)], 
and high-density lipoproteins (HDL)(Mahley et al. 1984). In spite of possible 
contaminations with adjacent lipoprotein fractions, ultracentifugation has remained 
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as a golden standard for lipoprotein research. According to their electrophoretic 
mobility, lipoproteins are classified to α, preβ, and β lipoproteins that are HDL, 
VLDL, and LDL classes, respectively. Also chromatographic methods based on the 
size of lipoprotein particles or their immunoaffinity have been used for separation of 
different lipoprotein subclasses. High-resolution nuclear magnetic resonance (NMR) 
spectroscopy is a new technique to separate lipoprotein subclasses according to their 
different size (Langlois and Blaton 2006). Some of the small-size HDL and LDL 
particles are particularly atherogenic, therefore the possibility to separate these 
subclasses and estimate their proportion in the whole particle population could 
improve the risk assessment of CVD (Rizzo and Berneis 2006a, Movva and Rader 
2008). 
Because lipoproteins are a heterogeneous group of particle populations differing 
in density, size, and lipid compositions, the other alternative to classify them is 
according to their major apolipoproteins (Mahley et al. 1984). All other lipoproteins 
except HDL contain apoB-48 (chylomicrons) or apoB-100 (VLDL, IDL, LDL, 
Lp[a]), which makes it possible to assess the amount of atherogenic lipoprotein 
particles in the circulation by the apoB measurement. The major apolipoproteins of 
HDL particles are apoA-I and apoA-II. Apolipoproteins A-I, A-II, C-I, C-II, C-III, 
and E can exchange between lipoproteins during the metabolism whereas apoB-48 
and apoB-100 are non-exchangeable. More details of lipoproteins’ characteristics 
are shown in Table 2. 
All lipoproteins share a similar particle structure: phospholipids, unesterified 
cholesterol, and apolipoproteins are on the surface and triacylglycerols, cholesterol 
esters and other neutral lipids are situated in the core of the particle. Apolipoproteins 
determine the metabolism of lipoproteins: they direct lipoprotein transport and 
redistribution between tissues, function as cofactors for a variety of enzymes, and 
maintain the structure of lipoproteins (Mahley et al. 1984).  
2.4 Metabolism of lipoproteins 
Lipoproteins transport lipids from the intestine and liver to the peripheral tissues. 
During their metabolism lipoproteins exchange apolipoproteins with each other and 
modify their lipid composition with the exception of apoB-48 and apoB-100 (Vance 
and Vance 2002). The role of VLDL and LDL particles is to deliver cholesterol, 
triglycerides, and other lipids to peripheral tissues in a process called forward 
cholesterol transport. Instead, HDLs transport excess cholesterol from the peripheral 
cells back to the liver in a process called reverse cholesterol transport (RCT) (Lewis 
and Rader 2005). Finally, all lipoproteins are catabolised in the liver, kidney or 
peripheral tissues via apolipoprotein-receptor-interactions or other mechanisms 
(Bamba and Rader 2007).  
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Table 2. The density, diameter, and apolipoprotein composition of lipoproteins. 
Lipoprotein class Density (kg/l) Diameter (nm) Apolipoproteins 
Chylomicrons <0.94a 80 – 1200d B-48, C-I, C-II,  
C-III, E 
Very low-density lipoprotein 0.94 – 1.006a 30 – 80d B-100, C-I, C-II,  
C-III, E 
Intermediate-density lipoprotein 1.006 – 1.019c 23 – 35d   B-100, C-II, C-III, E 
Low-density lipoprotein 1.006 – 1.063a 18 – 25d B-100 
Small dense low-density lipoprotein 1.050 – 1.063e 22 – 25.5f B-100 
Lipoprotein(a) 1.040 – 1.130h 25 – 30h Apo(a), B-100 
High-density lipoprotein, total 1.063 – 1.210a 5 – 12d A-I, A-II, C-II, C-III, 
E 
High-density lipoprotein HDL2 1.063 – 1.125b 9 – 12g  A-I, A-II, C-II, C-III, 
E 
High-density lipoprotein HDL3 1.125 – 1.210b 6 – 9g  A-I, A-II, C-II, C-III, 
E 
a  (Vance and Vance 2002), b (Langlois and Blaton 2006), c (Nauck 2002), d  (Contois et al. 2011), 
e (Campos et al. 1992), f  (Sacks and Campos 2003), g (Betteridge et al. 1999), h (Burtis et al. 2008) 
2.4.1 Chylomicrons and very low-density lipoproteins 
Chylomicrons are secreted from the intestine after a fat-containing meal with 
apolipoprotein B-48 as a major protein component. They deliver fat as an energy 
source for muscles or to adipose tissue for storage. Chylomicrons contain also apoC-
I, apoC-II, apoC-III, and apoE. For lipoprotein lipase (LPL) to function properly, 
they receive more apoC-II from HDL. After lipolysis of triglycerides with LPL, 
chylomicron remnants containing most of their cholesterol are taken up by the liver 
via LDL receptor pathway or LDL receptor-related protein (LRP), which both use 
apoE as a ligand on chylomicron remnant particle (Fujioka and Ishikawa 2009).  
The liver uses free fatty acids from the circulation and excess carbohydrates, fat, 
and proteins from the meal to synthesize triacylglycerides, which form very low-
density lipoproteins (VLDL) together with apolipoprotein B-100, cholesterol and 
other lipids. ApoB synthesis is highly regulated by the availability of core lipids, the 
type of dietary fatty acids, and by the hormonal balance (Ginsberg and Fisher 2009). 
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2.4.2 Low-density lipoprotein 
The end-point of VLDL-metabolism is LDL, which is the most cholesterol-enriched 
(majority cholesterol esters) lipoprotein particle in the blood circulation. LDL is 
responsible for constant supply of essential cholesterol for tissues and cells. The only 
protein in LDL particles is apoB-100, which is derived from the VLDL and does not 
exchange between other lipoproteins during metabolism (Prassl and Laggner 2008). 
The LDL population is subdivided into large, medium, small, and very small particles 
(Rizzo and Berneis 2007). The prevalence of small particles varies with age, sex, 
genetic factors, and diet being 30 – 35 % in adult men, 5- 10 % in men under 20 years 
and premenopausal women, and 15 – 25 % in postmenopausal women (Rizzo and 
Berneis 2006b). LDL is endocytosed into the cells via the LDL or B/E receptors, or by 
the scavenger receptor pathway. Trigyceride-rich VLDL remnants are transformed in 
some cases to small, dense LDL (sd-LDL) particles, which are more atherogenic than 
the buoyant, large ones. Small LDL particles have lower affinity to normal LDL 
receptors, but increased binding to proteoglycans in arterial intima. This receptor-
independent retention of LDL in subendothelial space overrides the normal regulation 
of cholesterol metabolism leading to the accumulation of cholesterol in extrahepatic 
tissues (Galeano et al. 1998).  
LDL can be separated into phenotype A with large, buoyant particles and to 
phenotype B with small, dense particles. The proportion of phenotype B increases 
with increasing triglyceride levels and decreased levels of HDL-C. This lipid 
combination has been defined as atherogenic lipoprotein phenotype and is a typical 
feature connected to MetS (Austin et al. 1990). These small LDL particles are more 
easily oxidized; one possible reason could be the increased content of 
polyunsaturated fatty acids (Rizzo and Berneis 2006b). 
2.4.3 High-density lipoprotein 
High-density lipoproteins (HDL) are secreted from the liver (70 %) or intestine (30 
%) as lipid-poor nascent particles that contain only apolipoprotein A-I and 
phospholipids. The maturation of HDL from nascent discoidal particle to larger, 
spherical HDL demands the action of lecithin-cholesterol acyltransferase (LCAT), 
which converts free cholesterol to cholesterol esters (Scanu and Edelstein 2008). 
These cholesterol esters are partly exchanged with triglycerides from apoB-
containing lipoproteins via cholesterol ester transfer protein (CETP) function before 
transport to the liver for catabolism as a part of reverse cholesterol transport (Lewis 
and Rader 2005). HDLs are further divided into larger, cholesterol ester-rich HDL2 
particles and smaller HDL3 particles (Movva and Rader 2008). Other details on 
interconversion of HDL, LDL, and VLDL are shown in Figure 1. Excess 
carbohydrates and sugar in the diet may cause endogenous hypertriglyceridemia, 
which activates CETP and hepatic lipase (HL) leading to formation of small-size 
HDL particles (Gou et al. 2005).  
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In addition to apolipoproteins A-I and A-II, HDL contains several other 
lipoproteins, enzymes, and other components, which are essential for its 
antiatherogenic, anti-inflammatory and antiapoptotic properties (Movva and Rader 
2008, Gordon et al. 2011). When fasting, apolipoproteins C-I, C-II, and C-III are 
mainly associated with HDL, but they are exchanged to the surface of chylomicrons 
or VLDL after fat-containing meal. After the lipolysis of triglycerides in 
chylomicrons and VLDL, these apolipoproteins are recycled back to HDL pool. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The metabolism of HDL particles in connection to LDL and VLDL 
 (modified from Langlois and Blaton 2006). ABCA-I = ATP binding 
 cassette transporter A-I, CE = cholesterol esters, CETP = cholesterol 
 ester transfer protein, FC = free cholesterol, HL = hepatic lipase, LCAT = 
 lecithin-cholesterol acyltransferase, PLTP = phospholipid transfer protein, 
 PL = phospholipids, TG = triglycerides 
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2.4.4 Atherosclerosis 
Early signs of atherosclerosis are characterized by excessive apoB-containing 
lipoproteins – chylomicron remnats, VLDL remnants, LDL, or Lp(a) – accumulation 
in the subendothelial space of the arterial wall (Ginsberg and Fisher 2009). Under 
normal conditions, excess cholesterol is removed from subendotelial space via RCT. 
When the amount of atherogenic particles exceeds the RCT capacity of HDL 
particles, cholesterol starts to accumulate into monocyte-derived macrophages 
leading to the formation of foam cells (Stancu et al. 2012). The risk of CVD is 
directly associated to total cholesterol or LDL-C concentrations and inversely to the 
HDL-C concentration. However, high LDL-C is only one of the predicting factors 
for atherosclerosis; the increasing amount of sd-LDL is even more powerful risk 
factor (Superko 1996). 
Raising the HDL-C by CETP-inhibition has clearly demonstrated that the 
mechanistic increase of total HDL-C does not necessarily lead to the risk reduction 
of CVD (Landmesser et al. 2012). The functionality of HDL in the reverse 
cholesterol transport and in the other atheroprotective mechanisms, including the 
stimulation of endothelic nitric oxide production and antioxidant activation, is more 
important than simply the HDL-C concentration in the circulation (Bandeali and 
Farmer 2012).  
2.5 The role of obesity and metabolic syndrome 
MetS is definied as a combination of obesity, hypertriglyceridemia, hyperglycemia, 
hypertension, and low HDL-C. Other features of MetS are endothelial dysfunction, 
insulin resistance, and proinflammatory and prothrombotic states. Various 
organizations have set different definitions for MetS with slightly different cutpoints 
(Alberti et al. 2009).  
When energy supply exceeds the energy consumption, excess energy is stored 
into adipose tissue in a form of triglycerides. The first route to adipose tissue is 
directly from a fat-containing meal transported by chylomicrons. The second route is 
through the liver, where excess carbohydrates, proteins and free fatty acids are 
metabolized into triglycerides and packed to VLDL particles (Verges 2010). 
Triglyceride-rich VLDL particles are transformed into sd-LDL particles, which 
contain less cholesterol than normal, more buoyant LDL. A low-fat, high-
carbohydrate diet has been revealed to be an important dietary factor behind 
atherogenic dyslipidemia triad: high triglycerides, low HDL-C, and increased small, 
dense LDL particles (Krauss 2001). This atherogenic triad is common for patients 
having CAD, MetS, insulin resistance, type 2 diabetes, and non-coronary forms of 
atherosclerosis ( Carmena et al. 2004, Avramoglu et al. 2006, Bamba and Rader 
2007, Rizzo and Berneis 2007, Choi and Ginsberg 2011). Sd-LDL particles have 
been shown to predict cerebro- and cardiovascular events in the future especially in 
connection with MetS (Rizzo et al. 2008). 
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2.6 Laboratory diagnostics of dyslipidemia 
For decades the risk assessment for cardiovascular diseases has been based on the 
total serum cholesterol and calculated LDL-C by the Friedewald formula. After 
introducing HDL-C as a secondary treatment target in NCEP’s guidelines, the 
precipitation-based assays for HDL-C have been replaced by less tedious 
homogenous methods. For precise and accurate measurements of cholesterol, HDL-
C, and triglycerides, NCEP has introduced performance goals for laboratories (Table 
3). To meet these performance goals, clinical laboratories should use methods which 
are traceable to the CDC reference methods. 
Table 3. Performance goals according to NCEP recommendations (Warnick et al. 
 2002).  
Lipid Biasa CVb Total error 
Cholesterol 3 % 3 % 9 % 
HDL-C 5 % 4 %c 13 % 
LDL-C 4 % 4 % 12 % 
Triglycerides 5 % 5 % 15 % 
a Bias from the reference value, b Correlation of variation., c HDL-C > 1.1 mmol/l; when HDL-C<1.1 mmol/l,  
SD<0.044 mmo/l  
 
The Centers for Disease Control and Prevention (CDC) has organized the Lipid 
Standardization Program since 1950s for total cholesterol, triglycerides, HDL-C, 
LDL-C, and recently also for apoA-I and apoB measurements. CDC also maintains 
the Cholesterol Reference Method Laboratory Network (CRMLN), which assists 
diagnostics manufacturers in validating their calibrators (Warnick et al. 2002). 
2.6.1 Measurement of cholesterol 
For fifty years CDC’s reference method for cholesterol measurements has been a 
modification of Abell-Kendall colorimetric method (Abell et al. 1952). First 
cholesterol esters are released with alcoholic potassium hydroxide by saponification 
from lipoproteins. After hexane extraction, Liebermann-Burchard reagent is used to 
form a chromophore for colorimetric measurement (Zak 1977). Liebermann and 
Burchard discovered in 1890s that a mixture of sulfuric acid and acetic acid with 
acetic anhydride produced a characteristic colour with cholesterol in gallstones. 
Unfortunately, colorimetric methods with strong acids are not easily standardized 
and they are not well-suited for automated clinical chemistry analyzers. However, 
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for ninety years cholesterol measuments were based on this hazardous techonology 
in clinical laboratories (Rifai et al. 2004). 
The next step in the evolution for analyzing cholesterol in serum was the 
discovery of specific enzymatic reagents in the early 1970s (Zak 1977, Rifai et al. 
2004). Cholesterol is distributed in serum between different lipoprotein fractions as 
free cholesterol and in esterified form. Thus, first cholesterol esters must be 
hydrolyzed by cholesterol esterase enzymes to receive all cholesterol available for 
analysis. In the next phase, cholesterol is oxidized to cholestenone and hydrogen 
peroxide is liberated. This hydrogen peroxide is then quantified usually in a reaction 
producing a chromophore.  
The concern about the comparability of cholesterol measurements emerged 
already in the 1950s and CDC established a cholesterol methodology development 
laboratory and standardization office in the end of 1950s (Rifai et al. 2004). Since 
then CDC has organized a Lipid Standardization Program for laboratories and 
reagent manufacturers. CRMLN has maintained the Abell-Kendall cholesterol 
reference method, which has been standardized by CDC. Recently, a new gas 
chromatography-isotope dilution mass spectrometry (GC-IDMS) procedure has been 
proposed to replace the former colorimetric reference method (Edwards et al. 2011). 
2.6.2 Measurement of triglycerides 
Most of the serum triglycerides (TG) are in triglyceride-rich lipoproteins: 
chylomicrons and VLDL. Triglycerides are measured as the amount of glycerol in 
serum, so also mono- and diglycerides are included. The first in-house method for 
triglyceride measurements was introduced in 1966 at CDC (Stein and Myers 1995). 
First the serum lipids were extracted with chloroform and then phospholipids and 
free glycerol were removed by silicic acid. An aliquot of the sample was saponified 
and the released glycerol was oxidized to formaldehyde. Finally, formaldehyde was 
reacted with chromotropic acid to form a chromogen, whose absorbance can be 
measured. 
Since 1970s enzymatic methods have replaced chemical methods in clinical 
laboratories. In the first step triglycerides are hydrolyzed to glycerol and fatty acids 
by lipase. Glycerol is then transformed to glycerol-3-phosphate with release of 
adenosine 5-diphosphate (ADP), which both can be used for measuring triglycerides. 
Most of the TG assays use glycerol phosphate oxidase (GPO) to generate hydrogen 
peroxide, which is reacted with peroxidase to give a red dye. Free glycerol in 
specimen may cause erroneous results in both chemical and enzymatic methods. To 
avoid the use of obsolete instrumentation and toxic chemicals CDC has developed a 
new reference method procedure by isotope dilution GC-MS (ID-GC-MS) (Edwards 
et al. 2012).  
Blood samples for triglyceride measurements should be taken after at least a nine 
hours fasting in order to avoid chylomicrons in the sample, which may increase TG 
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concentration. In the Friedewald equation it is assumed that most of the triglycerides 
are in the VLDL fraction so when post-prandial chylomicrons are abundant, this 
equation should not be used (Friedewald et al. 1972).  
2.6.3 Measurement of HDL-C 
High-density lipoproteins (HDL) are a heterogeneous group of lipoproteins that are 
the densest and smallest of all lipoprotein particles. These physical and chemical 
characteristics have been used to separate HDL particles from the other apoB-
containing lipoproteins (Langlois and Blaton 2006). The combination of 
apolipoproteins in HDL particles has an impact on the measument of HDL-C: the 
HDL subclass enriched with apoE may or may not be included in the concentration 
of HDL-C in different methods (Warnick et al. 2001). ApoE-rich HDL being larger 
and less dense than other HDL particles precipitate together with apoB-containing 
particles, when dextran sulphate is used, but not with heparin/manganese (Gibson et 
al. 1984). 
First generation HDL-C methods used polyanions with or without divalent 
cations to precipitate all other lipoproteins except HDL (Finley et al. 1978). After a 
centrifugation step, cholesterol was analyzed from the supernatant. The early 
applications used heparin with MnCl2 for precipitation, but this combination 
emerged to be inadequate for proper measurements of HDL-C. The next methods 
used dextran sulphate or phosphotungstic acid (PTA) in combination with Mg2+ ions. 
A major interfering issue with precipitation techniques has been the increased 
amount of triglycerides in lipoproteins, which make them lighter and cause 
incomplete precipitation. 
When HDL-C measurements became more common in clinical chemisty 
laboratories in 1990s, attempts to eliminate the tedious precipitation step led to 
second-generation methods. One of these methods used encapsulated iron beads 
linked to dextran sulphate to separate apo B-containing lipoproteins from HDL by a 
magnet. When compared to precipitation methods, a small negative difference to the 
dextran sulphate method and a positive difference to PTA method were observed 
(Warnick et al. 2001). 
The third generation HDL-C assays are homogeneous, direct methods without a 
precipitation step. The first innovations used polyethylene glycol to separate apo B–
containing chylomicrons, VLDL, and LDL particles from HDL particles. The next 
finding was to introduce sulphate α-cyclodextrin together with Mg2+ for blocking 
chylomicrons and VLDL particles (Sugiuchi et al. 1995). After this step, 
polyethylene glycol (PEG)-modified enzymes reacted with cholesterol in HDL 
particles leaving larger LDL particles intact. Other homogeneous assays have used 
antibodies against apoB and apoC, synthetic detergents, or selective enzymes which 
react only with cholesterol in other lipoproteins than HDL. One example of the latter 
modification of homogeneous methods utilizes an accelerator for the reaction of 
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cholesterol oxidase with non-HDL cholesterol. In the other reaction a specific 
detergent solubilizes specifically HDL particles for the cholesterol measurement. 
These commercial homogeneous assays have improved the precision via the better 
repeatability in pipetting and better control of the reaction temperature and timing, 
but specificity on specimens with unusual lipoproteins is still a problem (Miller et al. 
2010).  
The CDC´s reference method for HDL-C combines ultracentrifugation of 
chylomicrons and VLDL partices with precipitation of apoB-containing lipoproteins 
by heparin and MnCl2 (Warnick et al. 2001). Because few laboratories have 
possibilities for ultracentrifugation, CRMLN developed a designated comparison 
method (DCM) without the ultracentrifugation step (Kimberly et al. 1999). This 
method is based on dextran sulphate (50 000 kDa) and MgCl2 as a precipitation 
reagent.  
NCEP has set the analytical performance goal for measuring HDL-C with <5% 
bias from the reference value (Warnick and Wood 1995). However, dyslipidemia 
and other conditions with atypical lipoprotein characteristics (size, density, and 
charge) may cause discrepant results with different HDL-C methods. High 
triglyceride, haemoglobin, bilirubin and monoclonal paraprotein concentrations may 
also interfere with some HDL-C methods (Langlois and Blaton 2006). 
2.6.4 Measurement of LDL-C 
The first methods for LDL separation have been the same – ultracentrifugation and 
electrophoresis – as for HDL (Nauck et al. 2002). ApoB is an arginine- and lysine-
rich, positively charged protein, which has been the basis for most of the 
precipitation and homogeneous HDL-methods. Because the LDL particle population 
is diverse containing large size-variation, the reference method for LDL-C has been 
difficult to develop. The current basis for accuracy of LDL-C measurements is a 
combination of ultracentrifugation and polyanion precipitation, so called β-
quantification (Bachorik and Ross 1995). First chylomicron and VLDL fractions are 
removed by ultracentrifugation at density 1.006 kg/l.  LDL, IDL and Lp(a) are then 
precipitated by heparin-Mn2+ and the cholesterol concentration is measured by the 
Abell-Kendall reference method.  LDL-C is calculated by the difference of these 
fractions.  
The Friedewald formula has been the basic method for calculating LDL-C 
concentrations in many epidemiological studies and the cut-off values are based on 
these data (Friedewald et al. 1972). The Friedewald formula combines total 
cholesterol, HDL-C and triclycerides in the following equation: total cholesterol 
(mmol/l) – HDL-C (mmol/l) – triglycerides (mmol/l)/2.2. Because the presence of 
chylomicrons affects the estimation of the triglyceride fraction, fasting samples are 
needed for calculated LDL-C. The accuracy of Friedewald formula decreases 
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already when TGs are >2.6 mmol/l, but adequate estimates can still be obtained with 
TGs received up to 4.0 mmol/l (Marniemi et al. 1995).  
Homogeneous assays for LDL-C have been developed and they should be used 
especially when the triglyceride concentration is higher than 4.5 mmol/l (Warnick et 
al. 2002). Currently, there are several different homogeneous LDL-C assays based 
on selective detergents or other elimination methods to separate chylomicrons, 
VLDL, and HDL from LDL (Contois et al. 2011). A precipitation assay for sd-LDL 
cholesterol (sd-LDL-C) has also been developed (Hirano et al. 2009). According to 
the latest evidence, homogeneous LDL-C assays have limited specificity against 
unusual specimens, which may cause misclassification of patients (Miller et al. 
2010). Different LDL-C assay kits may react partially also to VLDL, IDL, Lp(a), or 
apoE-rich HDL particles producing variations in LDL-C concentrations ( Nauck et 
al. 2002, Iizuka et al. 2012). 
NCEP ATP III has accepted the sd-LDL as a novel cardiovascular risk factor, but 
the measurement of LDL particle size has not been transformed into clinical practice. 
However, the amount of all apoB-containing particles is possible to estimate with 
apoB measurements instead of LDL-C (Davidson 2008).  
Lipoprotein(a) [Lp(a)] consists of a LDL-like particle with an additional 
apolipoprotein(a) attached via a disulfide bond to apoB-100. Apo(a) is synthetized in 
the liver with structural homology with plasminogen. Lp(a) increases the CVD risk 
via macrophage foam cell formation and prothrombotic effects (Dube et al. 2012). 
The origin of Lp(a) synthesis is still obscure, but apo(a) is apparently attached to 
apolipoprotein B-containing lipoproteins extracellularly (Nordestgaard et al. 2010).  
2.6.5 Measurement of non-HDL-C 
ATP III included non-high-density lipoprotein cholesterol (non-HDL-C) as a new 
secondary target for therapy in the NCEP ATP III guidelines (Warnick et al. 2002). 
The aim was to increase the impact of triglyceride-rich lipoproteins to the screening 
and treatment guidelines. Non-HDL-C combines all apoB-containing atherogenic 
particles: VLDL, IDL, LDL, and Lp(a). Non-HDL-C is calculated by subtracting the 
concentration of HDL-C from the total cholesterol. The non-HDL-C should be 
measured if the LDL-C treatment goal has been achieved but the triglyceride 
concentration is still high. However, according to a meta-analysis of LDL-C, non-
HDL-C, and apoB as markers for cardiovascular risk, non-HDL-C was reported to 
be better than LDL-C, but apoB was superior to both LDL-C and HDL-C 
(Sniderman et al. 2011). 
2.6.6 Measurement of apoA-I and apoB 
The analytical difficulties with homogeneous HDL-C and LDL-C measurements 
have inspired the debate on apoA-I and apoB as alternatives for the risk assessment 
of cardiovascular disease. ApoB as a major protein of LDL and apoA-I of HDL 
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could be used to measure the amounts of these atherogenic and anti-atherogenic 
lipoprotein particles. Also measuring apoB concentration in serum is a better 
estimate of the number of atherogenic, sd-LDL particles than LDL-C (Davidson et 
al. 2011).  The increasing number of these particles is prevalent in patients with 
abdominal obesity, MetS, diabetes, hypertriglyceridemia, and low HDL-C; LDL-C 
concentration, however, is generally normal (Brunzell et al. 2008). 
Apolipoproteins have been measured by different methods: immunodiffusion, 
radioimmunoassays, enzyme-linked immunoassays, immunonephelometry, or 
immunoturbidimetric assay (Albers and Marcovina 1989). The lack of 
standardization for apoA-I and apoB measurements has prevented their use in 
cardiovascular risk assessment guidelines, but nowadays proper reference materials 
for apoA-I and apoB are available (Marcovina et al. 1993, Marcovina et al. 1994).  
Because total cholesterol, LDL-C and apoB are highly correlated, the same value 
of the 75th percentile as for LDL-C has been suggested to be the target value also 
for apoB.  Respectively, because HDL-C concentrations below the 10th percentile 
have been classified as risk for CVD, the same cut-off value has been used for 
apoA-I (Albers and Marcovina 1989). Since the reference material for apoA-I and 
apoB was introduced, some population-based reference values have been reported 
(Leino et al. 1995, Contois et al. 1996a, Contois et al. 1996b).  
CDC adopted apoA-I and apoB measurements as a part of the Lipid 
Standardization Program in 2010 with designated comparison methods, because real 
reference methods have not been implemented at the present. The proper 
measurement of apolipoproteins demands co-operation of reference laboratories, 
reagent manufacturers, and national advisory boards responsible for guidelines for 
risk assement of CVD (Albers and Marcovina 1989). 
The national guidelines have emphasized the use of total cholesterol and LDL-C 
for CVD risk assessment. However, the latest evidence has revealed that after 
reaching the therapeutic target for LDL-C, a substantial risk for CVD still remains. 
Many epidemiological studies have shown that apoB or apoB/apoA-I ratio might be 
a better predictor for cardiovascular risk than traditional cholesterol measurements 
(Walldius et al. 2001, Yusuf et al. 2004, Sniderman et al. 2006, Barter et al. 2006, 
Contois et al. 2009). 
2.6.7 Other techniques to analyse lipoprotein subpopulations 
Nuclear magnetic resonance (NMR) spectroscopy or gradient gel electrophoresis has 
been used to separate lipoprotein particles according to their size (Rizzo and Berneis 
2006a, Rizzo and Berneis 2006b). Also the efficiency of reverse cholesterol 
transport as facilitated by HDL particles has been investigated. The total number of 
particular LDL or HDL subpopulations or assessment of their functionality may be 
an even better approach than the apoB or apoA-I measurements, but the use of NMR 
or electrophoresis demands special equipment and so far are not suitable for clinical 
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practise. However, precipitation methods for sd-LDL-C and HDL-C in HDL2 and 
HDL3 subpopulatios have been developed (Hirano et al. 2008, Hirano et al. 2009). 
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3 Aims of the study 
The first aim of this study was to assess the accuracy of the laboratory methods used 
in the Finnish population-based surveys for the cardiovascular risk factors during the 
last four decades. The second aim was to calculate reference intervals for apoA-I, 
apoB, and apoB/apoA-I ratio and compare them with traditional cholesterol-based 
risk markers in different subgroups. The third aim was to assess the possibility to 
add apoA-I and apoB measuments to the diagnostics arsenal of dyslipidemia. 
 
 
Spesific aims of the study were to answer to the following questions: 
 
• Is it possible to measure accurately cardiovascular risk factors 
(cholesterol, HDL-C, and triglycerides) during several decades and what 
is the effect of systematic error to the interpretations of population 
trends (I, II, V)? 
 
• What is the effect of fasting and non-fasting on the triglyceride 
concentration when estimating the prevalence of high LDL-C and 
metabolic syndrome in population-based surveys (II, III)? 
 
• Do different homogeneous HDL-C methods classify people into 
different cardiovascular risk groups depending on the used methods (V)?  
 
• What new information does apoA-I, apoB, and apoB/apoA-I ratio give 
to the risk assessment for cardiovascular disease and metabolic 
syndrome (IV, V)? 
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4 Materials and methods 
4.1 The systematic error in measuring cholesterol,         
triglycerides, and HDL-C in population studies (I, II, V) 
4.1.1 External quality assessment programs 
The Laboratory of Analytical Biochemistry (TLAB) at the National Institute for 
Health and Welfare has participated in several external quality assessment programs 
since 1978. The Lipid Reference Program of World Health Organization (WHO) in 
1978 – 1997 and the national Labquality since 1978 have offered regulary external 
quality assessment (EQA) samples to the laboratory. TLAB has also attended to the 
EQA of the Canadian External Quality Assessment Laboratory (CEQAL) during the 
ten-year period 1993 – 2004 and CDC’s Lipid Standardization Program since 2001. 
The reference materials and source of target values in different EQA programs are 
shown in Table 4. We used data from these programs to assess precision and 
accuracy for serum cholesterol, triglycerides, and HDL-C measurements during four 
decades.  
Table 4. Reference materials and source of target values in external quality 
 assessment programs (EQA).  
EQA Reference material Target value 
WHO Lyophilized human sera CDC’s reference methods 
CEQAL Frozen human sera CDC’s reference methods 
CDC Frozen human sera CDC’s reference methods 
Labquality Lyophilized or fresh human sera 
or lyophilized animal sera 
Average of participants’results 
WHO: World Health Organisation, CEQAL: Canadian External Quality Assessment Laboratory, CDC: Centers 
for Disease Control and Prevention 
4.1.2 Population surveys 
The FINRISK population health surveys for cardiovascular risk factors have been 
carried out in five-year intervals since 1972 in Finland. Independent random samples 
stratified for age (25 – 64) and sex have been drawn from the population register. 
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The sample size has varied from 8000 to 13 500 subjects from 2 - 6 different regions. 
The protocol for sample collection has been the same in all surveys: venous blood 
samples have been drawn in a sitting position after at least a four-hour fasting 
between 11 am and 6 pm. After 30 min clotting time, samples have been centrifuged 
at 2200 g within one hour and the sera mailed daily to the laboratory until 2002. 
Since 2007, serum samples have been stored frozen at -20oC in the field centers for a 
few weeks and thereafter at -70oC before analyses.  
4.1.3 Laboratory analyses 
The methods, instruments, calibrators, and reagents have varied during four decades, 
but total cholesterol, triglycerides, and HDL-C measurements have been performed 
in the same laboratory of Analytical Biochemistry at the National Institute for 
Health and Welfare since 1970s. The reagent suppliers, instruments, and methods 
used in the laboratory are shown in Table 5 and Table 6. 
Table 5. Reagent suppliers and instruments for cholesterol, triglycerides, and 
 HDL-C measurements from 1972 at the National Institute for Health and 
 Welfare.  
Time period Reagent supplier Instrument 
1972 - 1979 Self-made  Auto Analyzer II, Technicon, 
USA 
1979 – 1998  Boehringer-Mannheim, 
Germany 
Nyegaard and Co AS Nyco-
test,Norwaya 
Olli-C, Thermo Fisher 
Scientific, Finland 
1998 - 2006 Thermo Fisher Scientific, 
Finland 
Optima 909, Thermo Fisher 
Scientific, Finland 
2006 -> Abbott Laboratories, USA Architect c8000, Abbott 
Laboratories, Abbott Park, IL, 
USA 
a 1980 – 1981 
4.1.4 Bias corrections for cholesterol and HDL-C 
The interpretation of changes in mean serum cholesterol and HDL-C concentrations 
in the Finnish population demands accurate information of real biases during the 
population surveys. Because EQA programs of WHO and CDC did not overlap in 
our laboratory, we had to estimate bias for cholesterol according to the bias between 
WHO/CDC versus Labquality. HDL-C results have been corrected according to the 
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biases at the time of FINRISK analyses. Details of bias corrections are reported in 
publications I and V. 
Table 6. Methods for cholesterol, triglycerides, and high-density lipoprotein 
 cholesterol (HDL-C) measurements from 1972 at the National Institute for 
 Health and Welfare.  
Cholesterol Triglycerides HDL-C 
Direct Liebermann-Burchard 
(1972 – 1979) 
Kessler and Lederer 
extraction/saponification/ 
fluorometry  
(1972 – 1977) 
Dextran-MgCl2  precipitation, 
enzymatic CHOD-PAP 
(1979 – 1998) 
Enzymatic CHOD-PAP 
(1979 ->) 
Fully enzymatic, UV-test 
(1977 – 1982) 
Homogeneous, polyethylene 
glycol-modified enzyme (PEG) 
(1998 – 2006) 
 Enzymatic GPO-PAP, 
colorimetric test 
(1982 – 2006) 
Homogeneous, accelerator 
selective detergent 
(2006 ->) 
 Enzymatic GPO 
(2006 ->) 
 
 
4.1.5 Statistical analyses 
Continuous variables have been presented as means with 95% confidence intervals 
(CIs) or standard deviation (SD). For method comparisons we used Bland-Altman 
difference plots, linear regression analyses, and paired t-tests. P-values <0.05 were 
considered statistically significant. All statistical analyses have been performed 
using Excel Analyse It –software or SPSS. 
4.2 Effects of fasting and non-fasting on serum triglyceride 
concentration (II, III) 
The effects of fasting on serum triglycerides were investigated from FINRISK 
population surveys in 1992, 1997, and 2002 from which triglyceride concentrations 
were available.  The final data included subjects whose triglyceride concentration 
was <10 mmol/l and fasting time 2 – 15 hours. We compared non-fasting (2 – 8 
hours for men, 2 – 7 hours for women) to overnight fasting with samples from 
FINRISK 2007 study followed by a substudy of the same participants later during 
the same year. Subjects were categorized as healthy when their BMI was <35 kg/m2, 
alcohol consumption was <90th percentile, they reported no CVD, cancer, or 
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medication for hypercholesterolemia, and they had normal blood pressure. The 
population health surveys were approved by the Ethical Committee of the Hospital 
District of Helsinki and Uusimaa and all participants gave a written informed 
consent. 
4.2.1 The kinetics of fasting 
We hypothesized that serum triglyceride concentration decreases after the last meal 
until it reaches a constant plateau. The first linear regression model was used to 
calculate the rate of decreasing triglyceride concentration and the second model 
represented the time after sufficient fasting time. The linear regression model log(tg) 
= a + b * fasting hours + c * sex + e was simplified to the relative change (exp(b) -1) 
*100. Estimates of relative change were calculated for all subjects and different 
subgroups: healthy, serum triglyceride concentration above 90th percentile or below 
25th percentile, and BMI>35 kg/m2. 
4.2.2 Correction of non-fasting triglycerides to fasting values 
Non-fasting triglyceride concentrations were transformed to fasting values using the 
correction factors for all subjects and different subgroups. Those subjects which had 
>7 hours fast for women and >8 hours fast for men in the first visit were chosen as 
the reference group. They also had to participate in the second study visit with a true 
fasting time. The correction factors for per hour of fasting were: 3.7 % for all, 4.3 % 
for healthy and 6.5 % for BMI>35 kg/m2. The correction was calculated to 7 hours 
fasting for women and 8 hours fasting for men. 
4.2.3 Statistical analyses 
The differences between corrected non-fasting and true-fasting triglyceride values 
were calculated with the Altman-Bland method showing the mean and 95% 
confidence intervals. Triglyceride concentrations were expressed as mean, median, 
and 25th and 75th percentiles. The Wilcoxon matched-pairs signed-rank test was 
used to calculate differences between groups and chi-square test for differences 
between prevalences. The total intraindividual biological variation for triglycerides 
was calculated in the reference group and for the whole group from both the non-
fasting and true-fasting visits. P-values <0.05 were considered statistically 
significant. The statistical analyses were performed using Microsoft Excel Analyse-
It software, Stata statistical package 10.1 (Stata Corporation 2007, Stata Statistical 
Software: Release 10.1 College Station, TX; StataCorp LP.), and IBM SPSS 
Statistics 19.  
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4.3 Reference intervals for apoA-I, apoB, and apo B/apoA-I 
ratio (IV) 
4.3.1 Reference population 
The FINRISK 2007 population-based health survey was used to calculate reference 
intervals for apoA-I, apoB, and apoB/apoA-I ratio. The reference population was 
selected from the total sample (n=6733) by excluding subjects without laboratory 
data (n=497) and subjects with self-reported CVD or cholesterol-lowering 
medication (n=1036), self-reported diabetes (n=198), obesity with BMI >30 kg/m2 
(n=608), or self-reported hypertension or antihypertensive medication (n=1566). The 
final reference population sample was 1528 women and 1300 men stratified by age 
with ten-year intervals from 25 to 74.  
4.3.2 Laboratory analyses 
The blood samples were taken according to the FINRISK protocol after at least a 
four-hour fasting period. ApoA-I and apoB were measured with Abbott Architect 
reagents by immunoturbidimetric methods (Abbott Laboratories, Abbott Park, IL, 
USA). The methods were standardized with WHO/IFCC reference materials SP1-01 
for apoA-I and SP3-07 for apoB. Cholesterol, triglycerides, and HDL-C were 
measured by Abbott reagents. LDL-C was calculated by the Friedewald formula, 
when the triglyceride concentration was <4.0 mmol/l. The inter-assay coefficients of 
variations (CV) and biases for cholesterol, triglycerides, HDL-C, apoA-I, and apoB 
are represented in Table 7. 
The final reference intervals, cut-off value, and therapeutic goals for apoB were 
bias-corrected with 8 %.  We analyzed also Certified Reference Material BCR-393 
(European Commision, Joint Research Centre Institute for Reference Materials and 
Measurements, Geel, Belgium) for apoA-I resulting in a bias of 2.6 % (+ 0.17). 
Certified reference material for apoB was not available. Because of the opposite 
results between CDC and reference material, ApoA-I results were not bias-corrected. 
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Table 7. Interassay coefficients of variation (CV) and biases for cholesterol, 
 triglycerides, HDL-C, apoA-I, and apoB.  
Analyte CV Bias 
Cholesterol 0.9 %a 1.0 % a 
HDL-C 2.2 % a -0.8 % a 
Triglycerides 1.1 % a -0.9 % a 
ApoA-I 1.4 – 2.0 %b -5 %c 
ApoB 2.1 – 3.8 %b -8 %c 
a According to the reference samples from CDC, b Depending on the concentrations of  daily quality control 
samples, c According to the reference samples from CDC and  in-house long-term quality control sample 
 
4.3.3 Statistical analyses 
Continuous variables were expressed as mean (+ SD) and differences between the 
mean values were assessed with t-test. The reference intervals for apoA-I, apoB, and 
apoB/apoA-I were calculated using 2.5th and 97.5th percentiles from the reference 
population using a nonparametric method. Outlier testing was done according to 
IFCC recommendations (Solberg 2004) with and without Horn algoritm (Solberg 
and Lahti 2005). Differences between the age groups were determined by analyses 
of variance (ANOVA) with Tukey’s post-hoc analysis. The healthy reference group 
and groups with selected diseases were compared with one-way ANOVA. For 
apoA-I, apoB and apoB/apoA-I cutoff values we used 10th, 25th, 50th, 75th, and 
90th percentiles in the reference group. The linear regression analysis was used to 
calculate correlation between LDL-C and apoB. Statistical analyses were performed 
by PASW Statistics for Windows version 18.0 (SPSS Inc. Chicago, IL, USA) and 
Excel Analyse-It software version 2.07 (Analyse-It software Ltd., City West 
Business Park, Leeds, United Kingdom). 
4.4 Comparisons of two HDL-C and apoA-I assays (V) 
Two homogeneous HDL-C and two immunoturbidimetric apoA-I methods were 
compared using freshly collected serum samples between the Laboratory of 
Analytical Biochemistry at the National Institute for Health and Welfare (THL) and 
the laboratory of Mehiläinen Laboratory Services (Mehiläinen) in Helsinki, Finland. 
Anonymous samples were received from the occupational health care of Mehiläinen. 
The protocol of method comparison was approved by the local Ethics Committee.  
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4.4.1 Laboratory analyses 
Cholesterol, HDL-C,  and apoA-I were measured by Abbott reagents (Abbott 
Laboratories, Abbott Park, IL, USA) at THL and by Thermo reagents (Thermo 
Fisher Scientific, Vantaa, Finland) at Mehiläinen. For HDL-C measurements, THL 
used a homogeneous, accelerator selective detergent (ASD) method and Mehiläinen 
used a PEG-modified enzyme method. ApoA-I concentrations were measured by 
immunoturbidimetric assays in both laboratories. The interassay coefficients of 
variation (CVs) are shown in Table 8. During the time of method comparison THL 
attended in CDC’s Lipid Standardization Program and biases compared to CDC’s 
reference methods were -0.6 % (+ 0.4) for cholesterol and       -0.3 % (+ 2.5) for 
HDL-C.  
Table 8. Interassay coefficients of variation (CV) for cholesterol, HDL-C, and 
 apoA-I at THL and Mehiläinen.  
Analyte CV (THL) CV (Mehiläinen) 
Cholesterol 0.6 % 1.5 %  
HDL-C 1.5 %  2.9 %  
ApoA-I 1.1 – 1.3 %a 2.4 – 2.7 %a 
a Depending on the concentrations of  daily quality control samples 
4.4.2 Statistical analyses 
The differences between methods were estimated with the Bland-Altman difference 
plot, Wilcoxon’s test for paired samples, and with Kappa statistic. For Kappa 
calculation we used the cut-off values of 1.0 mmol/l and 1.2 g/l for men and 1.2 
mmol/l and 1.4 g/l for women in HDL-C and apoA-I assays, respectively.  Statistical 
analyses were done with Excel Analyse-It software version 2.07 (Analyse-It 
software Ltd., City West Business Park, Leeds, United Kingdom. 
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5 Results 
5.1 The systematic error of cholesterol, triglycerides, and 
HDL-C measurements (I, II, V) 
5.1.1 Changes in cholesterol methods 
The different methods and instruments used during four decades at TLAB are 
introduced in Tables 5 and 6 in the Material and methods section. Auto Analyzer II 
(Technicon, USA) demonstrated no difference between the Liebermann-Burchard 
method and enzymatic CHOD-PAP-method, but applying the enzymatic method to 
an Olli-C analyzer (Thermo Fisher Scientific, Vantaa, Finland) decreased 
cholesterol concentrations by 2.3 %. The next change to an Optima analyzer 
(Thermo Fisher Scientific, Vantaa, Finland) did not result in significant differences 
during the method comparison. 
5.1.2 Changes in triglyceride methods 
Triglycerides have been measured with similar enzymatic methods since 1977, so 
only the instrument changes have caused possible systematic errors to the results 
(Tables 5 and 6). The change from Olli-C to Optima showed an average difference 
of 1.1 % (95% CI -8.2 to 10.3) in triglyceride values. The method for Optima 
analyzer had a secondary calibration instead of the previously used glycerol 
standards in methanol. The latest instrument change to an Architect analyzer 
demonstrated a difference of -3.1 % (95% CI -8.7 to 2.5) against the Optima 
analyzer. 
5.1.3 Changes in HDL-C methods 
The assays for measuring HDL-C have developed from the precipitation methods to 
direct, homogeneous ones during the last two decades (Tables 5 and 6). A new 
dextran sulphate (DS) lot purchased in 1987 decreased the HDL-C concentrations 
with 5.2 % and the difference was dependent on the HDL-C concentration. When 
HDL-C concentration was below 1.0 mmol/l, difference was -2.5 % (95% CI -3.8 to 
-1.4) compared to -12.8 % (95% CI -15.4 to -10.9) at HDL-C levels >1.5 mmol/l. 
The homogeneous PEG method yielded 4.0 % higher HDL-C concentrations than 
the DS precipitation method, and the difference was only slighty dependent on the 
HDL-C concentration. The final change to the ASD method had only a minor effect 
on the systematic error. 
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5.1.4 External quality assessment and population surveys 
TLAB has participated in both national and international external quality assessment 
programs since 1978. Details on the annual cholesterol, triglycerides, and HDL-C 
biases are presented in the publications I, II, and V, but the mean annual biases and 
biases during the FINRISK years are shown in Table 9 and Figure 2.  
Table 9. Mean annual biases of cholesterol, triglycerides, and HDL-C 
 measurements.  
Lipid Years Bias 95% CI 
Cholesterol 1978 - 2004 -0.7 % -0.9 –  -0.6 
Triglycerides 1978 - 2007 -1.5 % -2.3 –  -0.8 
HDL-C 1980 - 2012 -2.3 % -3.3 –  -1.4 
 
The cholesterol bias was quite stable until the end of 1990s, when the mean bias 
changed from negative to positive according to the CDC’s reference samples. A new 
calibrator lot introduced in 2000 increased cholesterol values, but since that EQA 
results have reached an almost zero bias during the FINRISK 2012 survey. The 
annual triglyceride bias has remained rather stable between the acceptance limit for 
different EQA programs: 8 – 18 % for WHO’s Lipid Reference Program and 5 – 15 
% for CDC’s Lipid Standardization Program. The precipitation methods for HDL-C 
showed an average bias of -4.7 % (95% CI -5.9 to -3.6), which changed to a slightly 
positive bias of +0.1 % (95% CI -0.7 to 1.0) after the homogeneous methods were 
adapted in the laboratory since 1998. 
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Figure 2. Mean annual biases for cholesterol, triglycerides, and HDL-C during the 
 FINRISK years 1982 – 2012. Results are from EQAs organized by WHO 
 (1982 – 1997) and by CDC (2002 – 2012). 
The decreasing trend for mean serum cholesterol concentration continued from 
1982 until 1997 in men and until 2007 in women (Tables 10 and 11). After bias-
correction in 2002, the same trend continued also in men until 2007. However, the 
mean cholesterol concentrations increased in the latest FINRISK 2012 survey,  1.7 
% in men and 3.1 % in women compared to the previous survey 2007 (Vartiainen et 
al. 2012). The mean HDL-C concentrations during the same FINRISK surveys have 
demonstrated positive trends with original data (P=0.053 for men and P=0.069 for 
women), but no trend was observed after bias-correction (P=0.816 for men and 
P=0.625 for women). The difference in HDL-C concentrations between men and 
women was on average 0.28 mmol/l (+ 0.02) during the entire observed period. 
 
 
 
 
 
 
.
.
.
.
.
.
.
.
.
.
.
Results 
 
THL — Research 101·2013 42 
Laboratory Diagnostics of 
Dyslipidemia 
 
 
Table 10. Mean cholesterol and HDL-C concentrations and cholesterol/HDL-C ratio 
 without and with bias-correction for men in FINRISK surveys 1982 -2012.  
Year Chol 
(mmol/l) 
Bias-
corrected 
Chol 
HDL-C 
(mmol/l) 
Bias-
corrected 
HDL-C 
Chol/HDL-C Chol/HDL-C 
Bias-
corrected 
1982 6.14 6.07 1.22 1.33 5.0 4.6 
1987 6.12 6.07 1.30 1.29 4.7 4.7 
1992 5.79 5.77 1.26 1.35 4.6 4.3 
1997 5.52 5.52 1.26 1.34 4.4 4.1 
2002 5.62 5.47 1.35 1.41 4.2 3.9 
2007 5.29 5.25 1.30 1.31 4.1 4.0 
2012 5.34a 5.34 1.33 1.31 4.0 4.1 
a Vartiainen et al 2012 
Table 11. Mean cholesterol and HDL-C concentrations and cholesterol/HDL-C ratio 
 without and with bias-for women in FINRISK surveys 1982 -2012.  
Year Chol 
(mmol/l) 
Bias-
corrected 
Chol 
HDL-C 
(mmol/l) 
Bias-
corrected 
HDL-C 
Chol/HDL-C Chol/HDL-C 
Bias-
corrected 
1982 6.06 5.98 1.46 1.58 4.2 3.8 
1987 5.95 5.91 1.58 1.57 3.8 3.8 
1992 5.58 5.55 1.52 1.63 3.7 3.4 
1997 5.47 5.47 1.54 1.64 3.6 3.3 
2002 5.44 5.29 1.64 1.71 3.3 3.1 
2007 5.19 5.15 1.56 1.58 3.3 3.3 
2012 5.31a 5.31 1.62 1.59 3.3 3.3 
a Vartiainen et al 2012 
 
We compared also the mean HDL-C concentrations from the precipitation 
method (1982 – 1997) and from the direct methods (2002 – 2012) using the results 
from the FINRISK surveys.  Before bias-correction HDL-C mean concentrations 
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were 5 % lower by the precipitation method compared to direct methods for both 
sexes, but after bias-correction no difference was observed (Table 12).  
Table 12. Mean HDL-C concentrations in men and women during 1982 -1997 
 (precipitation method) and 2002 – 2012 (direct methods) without and with 
 bias-correction.  
HDL-C 
(precipitation), 
mmol/l 
HDL-C 
(precipitation, bias-
corrected), mmol/l 
HDL-C  
(direct),  
mmol/l 
HDL-C  
(direct, bias-
corrected), mmol/l 
Men    
1.26a 1.33 1.33 1.34 
Women    
1.52a 1.61 1.61 1.63 
a Differed significantly (p<0.05)  from the bias-corrected by one-way Anova. 
 
 
5.2 Correction of non-fasting triglycerides to fasting 
triglycerides (II, III) 
5.2.1 Calculations of factors for transforming non-fasting to fasting 
triglycerides 
 
The fasting time before blood sampling in FINRISK surveys has been defined as a 
minimum of 4 hours, so most of the participants have fasted for 4 – 6 hours. The 
mean serum triglyceride concentrations for a fasting time of 2 – 8 hours from 
FINRISK surveys in 1992, 1997, and 2002 for all and healthy men and women are 
shown in Table 13. Triglyceride concentrations decreased during the first 8 fasting 
hours in men and the first 7 hours in women. We used this data to calculate the 
factors for relative changes per hour as shown in Table 14. 
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Table 13. Mean serum triglyceride concentratios for all and healthy men and 
 women in FINRISK surveys 1992, 1997 and 2002 per fasting time.  
Fasting time All men 
(n=10 460), 
mmol/l 
Healthy men 
(n=4246), 
mmol/l 
All women 
(n=11 624), 
mmol/l 
Healthy women 
(n=5017), 
mmol/l 
2 1.96 1.95 1.53 1.38 
3 1.93 1.67 1.42 1.22 
4 1.77 1.71 1.31 1.22 
5 1.71 1.59 1.24 1.14 
6 1.68 1.55 1.21 1.10 
7 1.56 1.44 1.14 1.02 
8 1.53 1.42 1.16 1.04 
 
Table 14. Relative change (95% CI) of serum triglyceride concentration per hour in 
 different groups in FINRISK surveys in 1992, 1997, and 2002.  
All 25th percentile 90th percentile Healthy BMI >35 
-3.7 [-4.2,-3.1] -2.3 [-2.7,-1.8] -5.3 [-6.2,-4.3] -4.3 [-5.2,-3.5] -6.5 [-8.7,-4.3] 
 
5.2.2 Converting non-fasting triglycerides to fasting values with factors 
We transformed non-fasting triglyceride concentrations to fasting values using the 
correction factors for all and different subgroups (Table 15 and Figure 3) and 
compared these results with true fasting values in FINRISK 1992, 1997, and 2002 
studies. 
We also compared statistically corrected non-fasting triglyceride values with true 
fasting values in the FINRISK 2007 survey. Using this data from the same subjects, 
we estimated the misclassification of subjects into the categories of high LDL-C or 
MetS with and without triglyceride correction (Table 16). The definition for MetS 
according to the NCEP (ATP III) uses triglyceride concentration > 1.7 mmol/l as 
one criterion for MetS (Grundy et al. 2005).  
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Table 15. Comparison of original and calculated 8 hour fasting triglyceride 
 concentrations for different subgroups in FINRISK 1992, 1997, and 2002 
 studies.  
Subgroup Original 8 h 
fasting TG, 
mmol/l 
Calculated 8 h 
fasting TG, 
mmol/l 
Original – 
calculated TG, 
mmol/l 
Difference,  
% 
25th percentile 0.68 0.68 0.00 0.0 
Healthy 1.29 1.30 -0.01 -0.6 
All 1.39 1.42 -0.03 -2.1 
BMI >35 1.78 1.66 0.12 6.9 
90th percentile 3.34 3.16 0.18 5.4 
 
 
 
 
Figure 3. The mean serum triglyceride concentration per hour using factors (Table 
 14) for different subgroups. 
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Table 16. Comparison of non-fasting, corrected non-fasting and true-fasting 
 triglyceride median concentrations [25th, 75th], and the prevalences of 
 LDL-C>3.00 mmol /l and metabolic syndrome in the FINRISK 2007 
 survey.  
Group Tg, mmol/l [25th, 75th] LDL>3.0 mmol/l Prevalence of 
metabolic 
syndromeb 
Non-fasting  1.18 a [0.87, 1.72] 51.3 % a 39.7 %a 
Non-fasting, 
corrected 
 1.06 a [0.78, 1.52] 54.8 % a 37.6 %a 
True-fasting 1.00a [0.75, 1.38] 56.4 % a 35.5 %a 
a p< 0.001compared to the other groups; b According to the National Cholesterol Education Program  ATP III 
(Grundy et al. 2005) 
 
The prevalences of MetS according to the criteria of International Diabetes 
Federation (IDF) and International Diabetes Federation Task Force (IDFTF) (Alberti 
et al. 2009, Alberti et al. 2005) were higher: 47.1 % and 49.8 % for non-fasting, 45.6 
% and 47.9 % after statistical correction compared to 44.8 % and 46.3 % in true-
fasting subjects in the same FINRISK 2007 study (P<0.0001 for all comparisons). 
The difference between the prevalences of MetS decreased from 4.2 % to 2.1 % with 
ATP III criteria and from 2.3 % and 3.5 % to 0.8 % and 1.6 % with IDF and IDFTF, 
respectively (P<0.0001 for all comparisons).  
5.3 Reference intervals for apoA-I, apoB and apoB/apoA-I ratio 
(IV) 
Reference intervals for apoA-I, apoB, and apoB/apoA-I ratio were calculated 
according to the 2.5th percentile and 97.5th percentile from the healthy reference 
group in the FINRISK 2007 study. The mean apoA-I and apoB concentrations, and 
apoB/apoA-I ratio in different age groups are shown in Figures 4, 5, and 6. The 
mean apoA-I concentrations were higher in women than in men in all age groups, 
but women reached the male apoB concentration by the age of 65. The apoB/apoA-I 
ratio increased in women during the whole observed time; whereas in men the ratio 
was quite stable after 35 years.  
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Figure 4. The mean serum apoA-I concentration for men and women in different 
 age groups in the healthy reference group from FINRISK 2007 study.  
 
Figure 5. The mean serum apoB concentration for men and women in different age 
 groups in the healthy reference group from FINRISK 2007 study.  
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Figure 6. The mean serum apB/apoA-I ratio for men and women in different age 
 groups in the healthy reference group from FINRISK 2007 study.  
The final reference intervals for apoA-I, apoB, and apoB/apoA-I are shown in Table 
17. ApoB values were bias-corrected (see Material and methods 4.3.2).  
Table 17. Reference intervals for apoA-I, apoB, and apoB/apoA-I ratio from the 
 healthy reference group from FINRISK 2007 study.  
Sex ApoA-I, g/l ApoB, g/la ApoB/apoA-I 
Men 1.1 – 2.0 0.6 – 1.5 0.3 – 1.0 
Women 1.2 – 2.3 0.6 – 1.3 0.3 – 0.8 
a Bias-corrected 
 
5.4 Comparison of lipids, lipoproteins, and apoA-I and apoB in 
different pathophysiological conditions (IV) 
 
The same groups, which were excluded from the healthy reference group in the 
FINRISK 2007 study, were used to assess the differences in mean concentrations of 
lipids, lipoproteins, and apoA-I and apoB between the healthy and non-healthy 
groups.  
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The mean cholesterol concentrations were 11 % and 12 % lower in men when 
having CVD or diabetes, but in women mean cholesterol concentrations had only a 
minor 1 % difference compared to the healthy reference group (Figure 7). The 
lowest HDL-C concentrations were observed in subjects with diabetes and obesity in 
both sexes: 14 % lower in men and 15 % lower in women in contrast to the 
reference group (Figure 8). LDL-C concentration was higher in men than in women 
in the healthy reference group, but in all disease groups women had higher LDL-C 
concentrations than men (Figure 9). The mean LDL-C concentrations were on 
average 20 % lower in men with self-reported CVD or diabetes, but in women LDL-
C was only 4 % lower in these disease groups compared to the healthy reference 
group. Triglyceride concentrations were 27 – 67 % higher in all disease groups 
compared to the healthy reference group in both sexes (Figure 10). The triglyceride 
concentrations were on average 55 % higher in men and 60 % higher in women with 
diabetes and BMI>30 than in the reference group. 
 
 
 
Figure 7. The comparison of mean total cholesterol (TC) for men and women in the 
 healthy reference group and different disease groups. * Did not differ 
 significantly from the healthy group (p<0.05; one-way ANOVA).Others 
 differed significantly from the healthy reference group. 
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Figure 8. The comparison of mean HDL-C for men and women in the healthy 
 reference group and different disease groups. All groups differed 
 significantly from the healthy reference group (p<0.05; one-way ANOVA). 
 
Figure 9. The comparison of mean LDL-C for men and women in the healthy 
 reference group and different disease groups. * Did not differ significantly 
 from the healthy group (p<0.05; one-way ANOVA). Others differed 
 significantly from the healthy reference group. 
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Figure 10. The comparison of median triglycerides (TG) for men and women in the 
 healthy reference group and different disease groups. All groups differed 
 significantly from the healthy reference group (p<0.05; one-way ANOVA). 
ApoA-I concentrations showed a similar pattern as the HDL-C concentrations for 
men and women: the lowest concentrations were observed in subjects with diabetes 
and obesity (Figures 8 and 11). Mean LDL-C concentrations were 6 % and 3 % 
lower in women having CVD or diabetes than in the healthy reference group, but 
both apoB and apoB/apoA-I ratios were on average 10 % higher in these disease 
groups (Figures 12 and 13). However, men had lower concentrations for both LDL-
C and apoB when having CVD. Obese men had the lowest apoA-I concentrations, 
the highest apoB concentrations, and the highest apoB/apoA-I ratio compared to the 
reference group. Obese women had 16 % higher apoB concentration and 24 % 
higher apoB/apoA-I ratio than women in healthy reference group. In addition, 
women had higher apoB concentrations and apoB/apoA-I ratios in all disease groups 
compared to the reference group. 
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Figure 11. The comparison of mean apoA-I for men and women in the healthy 
 reference group and different disease groups. * Did not differ significantly 
 from the healthy group (p<0.05; one-way ANOVA). Others differed 
 significantly from the healthy reference group. 
 
Figure 12. The comparison of mean apoB for men and women in the healthy 
 reference group and different disease groups. All groups differed 
 significantly from the healthy reference group (p<0.05; one-way ANOVA). 
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Figure 13. The comparison of apoB/apoA-I ratio for men and women in the healthy 
 reference group and different disease groups. * Did not differ significantly 
 from the healthy group (p<0.05; one-way ANOVA). Others differed 
 significantly from the healthy reference group. 
5.5 Defining cut-off values for apoA-I, apoB, and apoB/apoA-I 
ratio (IV) 
The comparison of 10th, 25th, 50th, 75th, and 90th percentiles for HDL-C, apoA-I, 
LDL-C, apoB, and apoB/apoA-I ratio are shown in Figures 14 and 15. The 10th 
percentile was used as a cut-off value for low HDL-C: 1.0 mmol/l for men and 1.2 
mmol/l for women (Albers and Marcovina 1989). The same 10th percentile for 
apoA-I caused cut-off values 1.2 g/l for men and 1.4 g/l for women. The 50th 
percentile for LDL-C was almost equivalent to the concentration of 3.0 mmol/l, 
which is a target value in the risk assessment for CVD in Europe (Graham et al. 
2007). At the same 50th percentile level apoB concentrations were the same 0.9 g/l 
for both sexes, and apoB/apoA-I ratios were 0.6 for men and 0.5 for women.  
 
The linear regression equations for calculating apoB from known LDL-C 
concentration are as follows: 
 
Men:  apoB = 0.2393 * LDL-C + 0.1466 (R2 = 0.87) 
Women: apoB = 0.2298 * LDL-C + 0.1460 (R2 = 0.87) 
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Figure 14. The comparison of HDL-C and apoA-I percentiles for women and men in 
 the healthy reference group in FINRISK 2007 study. 
 
 
Figure 15. The comparison of LDL-C, apoB, and apoB/apoA-I ratio percentiles for 
 women and men in the healthy reference group in FINRISK 2007 study. 
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The therapeutic goals for apoB (bias-corrected) are calculated according to the linear 
regression analyses corresponding to the serum LDL-C concentrations in different 
risk groups (Table 18). 
Table 18. The therapeutic goals for LDL-C and apoB. Goals are the same for men 
 and women (Graham et al. 2007). 
Analyte Low riskb High riskc Highest riskd 
LDL-C, mmol/l <3.0 <2.5 <2.0 
ApoB, g/la <0.9 <0.8 <0.7 
a Bias-corrected, b 0 – 1 risk factors, c Individuals with more than 1 risk factor or with CVD or diabetes 
d Individuals with CDV and diabetes  
 
5.6 Method comparisons of two direct HDL-C methods and 
immunoturbidimetric apoA-I methods (V) 
Two direct HDL-C methods and two immunoturbidimetric apoA-I methods were 
compared between two independent laboratories. The other laboratory used a PEG-
method (Thermo) and TLAB used an ASD-method (Abbott) for analysing HDL-C 
concentrations. The mean concentrations for cholesterol (5.06 mmol/l vs. 5.16 
mmol/l) and apoA-I (1.54 g/l vs. 1.61 g/l) differed between these two laboratories 
(P<0.001), but mean HDL-C concentrations (1.45 mmol/l vs 1.46 mmol/l) were 
almost the same (P=0.266).  
In spite of the same mean HDL-C concentrations, these two methods 
demonstrated concentration-dependent difference (Figure 16). The difference was 
negative with low HDL-C concentrations and turned to positive with higher 
concentrations (Table 19). The difference was significant at all concentration ranges 
(P<0.0001, Wilcoxon’s test).   
The agreements between PEG- and ASD-method for HDL-C and two 
immunoturbidimetric methods for apoA-I were calculated with Kappa statistic using 
previously defined cut-off values (Results 5.5). The results are shown in Tables 20 - 
23.  
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Figure 16. Scatter plot for Abbott and Thermo direct HDL-C methods. 
Table 19. Difference and 95% confidence limits between PEG-method (Thermo) 
 and ASD-method (Abbott) at different HDL-C concentrations (mmol/l).  
PEG  - ASD HDL-C<1.00  1.00<HDL-C<1.55 HDL-C>1.55  
Difference %  -12.0 %a -4.5 %a +9.0 %a 
95% CI [-13.5, -10.0] [-5.5, -4.0] [7.0, 10.5] 
a Wilcoxon’s test, P<0.0001 
Table 20.  Agreement between two direct HDL-C methods (reagents from Thermo 
 and Abbott) in women. The number shows how many of the samples 
 were classified to the same or different concentration class (n=40). 
Women HDL-C<1.00 (Thermo) 1.00<HDL-C<1.20 (Thermo) 
HDL-C<1.00 (Abbott) 2 0 
1.00<HDL-C<1.20 (Abbott) 11 27 
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Table 21. Agreement between two direct HDL-C methods (reagents from Thermo 
 and Abbott) in men. The number shows how many of the samples were 
 classified to the same or different concentration class (n=59). 
Men HDL-C<1.00 (Thermo) 1.00<HDL-C<1.20 (Thermo) 
HDL-C<1.00 (Abbott) 21 0 
1.00<HDL-C<1.20 (Abbott) 18 20 
 
Kappa value for two different HDL-C methods in women was 0.20 [95% CI -0.04, 
0.44] and in men 0.44 [95% CI 0.26, 0.62]. Kappa value 0.20 for women means 
slight agreement between methods and 0.44 for men shows moderate agreement 
(Sim and Wright 2005). Kappa values for two different apoA-I methods were better 
than for HDL-C methods: 0.55 [95% CI 0.31, 0.80] in women and 0.71 [95% CI 
0.47, 0.95] in men. Kappa value 0.55 for women shows also moderate agreement 
between methods, but 0.71 for men means substantial agreement.  
Table 22. Agreement between two different apoA-I methods (reagents from 
 Thermo and Abbott) in women. The number shows how many of the 
 samples were classified to the same or different concentration class 
 (n=50). 
Women ApoA-I<1.4 (Thermo) ApoA-I>1.4 (Thermo) 
ApoA-I<1.4 (Abbott) 14 2 
ApoA-I>1.4 (Abbott) 7 27 
 
Table 23. Agreement between two different apoA-I methods (reagents from 
 Thermo and Abbott) in men. The number shows how many of the 
 samples were classified to the same or different concentration class 
 (n=56). 
Men ApoA-I<1.2 (Thermo) ApoA-I>1.2 (Thermo) 
ApoA-I<1.2 (Abbott) 8 1 
ApoA-I>1.2 (Abbott) 4 43 
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6 Discussion 
The interpretation of trends in serum cholesterol, triglycerides, and HDL-C 
concentrations in population-based health surveys is demanding because of the 
possible systematic error in laboratory measurements between the survey years. 
Different factors affecting the systematic errors and interpretations of the trends 
were analysed during four decades of FINRISK population studies. Because a full 
12-hour fasting is often difficult to organize in population studies, factors for 
transforming non-fasting triglyceride concentrations to fasting values were 
calculated in different subgroups. The differences in prevalences of high LDL-C and 
metabolic syndrome were also estimated using non-fasting and true-fasting 
triglyceride concentrations. The introduction of new reference values for apoA-I, 
apoB, and apoB/apoA-I ratio among Finns should encourage clinicians to use apoA-
I and apoB measurements for CVD risk assessment, especially in certain risk groups.  
6.1 Changes in cholesterol, triglycerides, and HDL-C methods  
 
Cholesterol 
Already sixty years ago the causality of cholesterol in the etiology of atherosclerosis 
was discovered and accurate methods for measuring serum cholesterol in clinical 
laboratories were needed (Abell et al. 1952). Abell et al. developed a simplified 
method for measuring cholesterol, which was based on the liberation of cholesterol 
from serum lipoproteins by alcoholic potassium hydroxide. After saponification of 
cholesterol esters to free cholesterol and extraction into the petrol ether, cholesterol 
concentration was measured with the Liebermann-Burchard color reagent (Kenny 
1952). During two decades this was the “golden” method to measure serum 
cholesterol in clinical laboratories and after minor modifications it is still the CDC’s 
reference method.  
The most significant change in the era of cholesterol measurements has been the 
replacement of the Liebermann-Burchard method by enzymatic methods. This 
change occured in TLAB in the end of 1970s and yielded on average a 2.3% 
decrease in cholesterol results. Since then the cholesterol assay method has remained 
the same, changes have been made only through reagent suppliers, instruments, and 
calibrators. 
 
Triglycerides 
There have been only minor changes in triglyceride measurements after substituting 
enzymatic methods for chemical methods. Because triglycerides are measured as a 
glycerol concentration, increased concentrations of free glycerol in specimen may 
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cause erroneous results in both chemical and enzymatic methods. For example, 
recent exercise, liver disease, diabetes mellitus, or stress can increase endogenous 
glycerol concentration and cause overestimation of triglycerides (Stein and Myers 
1995).  
 
HDL-C 
When the protective role of HDLs in the progress of atherosclerosis was accepted in 
1970s, more convenient methods than ultracentrifugation to measure HDL-C were 
developed. Because the high-density lipoproteins are a highly heterogenous group of 
lipoproteins, it has been demanding to develop specific and accurate methods to 
quantify the cholesterol content in HDL particles. The main principle has been to 
separate apolipoprotein B-containing lipoproteins from the remaining high-density 
lipoproteins. The CDC’s reference method is based on the removal of VLDL 
particles by centrifugation followed by the precipitation of non-HDL particles by 
heparin with manganese. This precipitation method, however, has caused problems, 
because all heparin preparations have not been equally efficient in precipitating non-
HDL particles (Lopes-Virella et al. 1977). A major problem with precipitation 
methods has been a high triglyceride concentration, which has interfered with the 
proper precipitation of non-HDL lipoproteins (Warnick 2001 et al. 2001). In 
addition, the dextran sulphate with magnesium as a precipitation reagent has turned 
out to be more reliable with enzymatic assays (Rifai et al. 2004).  
The next innovation in HDL-C measurements has been the development of 
homogeneous, direct methods without the need for precipitation step in 1990s. 
These methods use different approaches to separate lipoprotein fraction from each 
other: particle size, charge, or density.  One of the first innovations was the use of 
PEG-modified enzymes with sulphated α-cyclodextrin (Sugiuchi et al. 1995). 
Sulfated α-cyclodextrin together with Mg2+ selectively blocked but did not precipate 
chylomicrons and VLDL particles. Cholesterol esterase and cholesterol oxidase 
modified with PEG showed selective catalytic activity towards different lipoproteins: 
HDL-C had the highest reactivity and LDL-C the lowest reactivity towards these 
enzymes. The PEG-method includes the apoE-containing HDL particles, instead of 
the PTA-method, which precitates these particles (Warnick et al. 2001). ApoE-
containing particles comprise on average 10 % of the total HDL population, and the 
same difference has been observed also in the method comparisons between PTA 
and dextran sulphate/heparin precipitation methods. In the method comparison we 
observed a 4 % increase in HDL-C concentrations with the PEG-method compared 
to the dextran sulphate precipitation method. Homogeneous methods have 
demonstrated better agreement with CDC’s reference method than previous 
precipitation methods, but discrepancies still exist.  
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6.2 Systematic error in cholesterol, triglycerides, and HDL-C 
measurements 
6.2.1 External quality assessment 
Actions to improve the accuracy of laboratory measurements started in early 1970s 
in Finland (Grönroos et al. 1984). The target values of EQA programs are usually 
based either on the average values of participants’ results or on the values measured 
by a reference method. The Finnish Labquality organization has offered EQA 
programs to clinical laboratories since 1971. TLAB has maintained EQA data from 
Labquality programs since 1978, WHO Lipid Reference Program 1978 – 1997, and 
CDC Lipid Standardization Program since 2001. For cholesterol and triglyceride 
measurements all these three programs have produced quite similar estimations for 
systematic error, but HDL-C measurements have turned out to be more complicated.  
TLAB has been able to maintain the systematic error for total cholesterol and 
triglycerides nearly within + 3 % and + 5 %, respectively, during the past four 
decades. Labquality’s EQA samples have demonstrated more variations in reference 
materials (lyophilized human or animal sera, fresh human sera), which may have 
resulted in larger systematic errors in these EQA samples. Lyophilization of serum 
samples can change the composition of lipoprotein particles so different enzymes 
reach cholesterol inside lipoprotein particles slower than in fresh serum samples 
(Kroll and Chesler 1990). The reaction rates in different methods may vary causing 
method-dependent biases compared to the reference method. The comparison of 
fresh-frozen and lyophized reference materials have been shown to result in 6 % 
lower results with lyophized sera compared to fresh frozen sera (Thienpont et al. 
2003).  
The assigned values of the calibrators are the most important factor affecting the 
systematic error of an analytical method. The different composition between 
lyophilized and fresh reference materials is a main cause for matrix effects, which 
have increased the preparation of commutable fresh or frozen reference materials 
(Cramb et al. 2008). The calibrator for lipid measurement should be fresh sera to 
avoid the matrix effect caused by lyophilized calibrators. In the end of 1980s CDC 
created the Cholesterol Reference Method Laboratory Network (CRMLN) to 
improve the traceability of commercial cholesterol assays to the reference method 
(Myers et al. 2000). The calibrators should show commutability with patient 
samples to avoid matrix effects and erroneous results in EQA programs and also in 
clinical practice (Warnick and Wood 1995).  
The precipitation method for analysing HDL-C concentrations showed an 
average -5 % bias compared to the CDC’s reference method during the entire period 
1980 – 1997. Because precipitation methods are based on different principles than 
direct methods to separate HDL from the other apoB-containing lipoproteins, 
method-dependent biases exist compared to the reference method. The experiences 
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concerning our own national EQA have shown a great variation in results between 
different manufacturers’ direct HDL-C assays. Because this has occured also with 
fresh serum samples, discrepancies are not related to matrix effect or non-
commutable samples. The solution by the national EQA to this problem was to 
separate different manufacturers’ assays to own result groups to achieve bias 
criterium. However, this practice obscures the differences between HDL-C methods 
and leads to an erroneous impression of the accuracy, which ultimately affects the 
risk scoring by the clinicians.  
6.2.2 Systematic error and interpretations of population trends 
Population trends have been measured since the 1970s in Finland first in cholesterol 
and triglyceride concentrations and later in HDL-C (Vartiainen et al. 2010). The 
same laboratory at the National Insitutute for Health and Welfare (former the 
National Public Health Institute) has been responsible for the laboratory 
measurements in FINRISK population studies since 1970s. During this time the 
mean cholesterol concentration in the Finnish population has decreased from nearly 
7 mmol/l close to 5 mmol/l. At the same time HDL-C concentrations have remained 
quite stable, on average 1.3 mmol/l in men and 1.6 mmol/l in women.  
According to our EQA data since 1982, the cholesterol bias has remained + 3 % 
compared to the CDC’s reference method. The systematic error has displayed only a 
minor effect when interpreting population trends. However, for example in 2002 the 
original data compared to the previous survey five years earlier, showed an 1.8 % 
increase for cholesterol in men and no change in women, but after bias-correction no 
change in men and -3.3 % change in women was found. The systematic error with 
an uncertainty (95% CI) has to be within quite narrow limits to make it possible to 
detect minor changes on a population level.  
Salomaa et al reported in 1991 that the HDL-C concentrations of the population 
had possibly increased from 1982 to 1987 (Salomaa et al. 1991). However, they did 
not take into account the systematic error in the laboratory measurements. Our data 
demonstrated in fact a -9 % bias in 1982 HDL-C concentrations compared to an 
almost zero bias in 1987. The original HDL-C concentrations from FINRISK studies 
1982 – 2012 showed a slightly positive trend, but after bias-correction this trend 
disappeared.  
The standardization of methods and pre-analytical factors is important when 
comparing the prevalences of hypercholesterolemia and other dyslipidemias 
between different countries (Tolonen et al. 2005). In spite of the fairly good 
precision of cholesterol measurements, conciderable systematic errors may exist 
between the laboratories. The laboratory measurements for Euroaspire I and II 
studies showed a 13 % difference between the cholesterol concentrations in two 
laboratories (EUROASPIRE I and II Group and European Action on Secondary 
Prevention by Intervention to Reduce Events 2001). The Diabetes Intervention 
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Study (DAIS) implemented a quality control program for the core laboratories, one 
in Canada and another in Finland (McGuinness et al. 2000). The Canadian 
Reference Laboratory assisted in the standardization and EQA samples for the core 
laboratories. This clinical trial succeeded well in maintaining the lipid and 
lipoprotein analyses within the allowable total error limits. Systematic and random 
errors in the laboratory measurements were identified and improved by the aid of the 
EQA program. 
6.3 Transforming non-fasting triglyceride concentrations to 
fasting values 
The overnight fasting is recommended to proper comparability of triglyceride 
concentrations, but in the population studies this demand is difficult to carry out. 
Triglyceride concentrations in serum increase after a meal and then start to decrease 
as the result of lipolysis by lipoprotein lipase. VLDL particles contain the most of 
the serum triglycerides in fasting condition.  Triglyceride-rich lipoprotein remnants 
are considered to have a role in the progress of atherosclerotic plaques, because they 
are small enough to penetrate the arterial wall (Chapman et al. 2011).  
The comparison of triglyceride concentrations in population studies is difficult, 
because of the different fasting period. This situation has also affected the 
calculations of LDL-C by Friedewald formula and the prevalences of metabolic 
syndrome. Our data from FINRISK studies 1992, 1997, and 2002 showed that 
triglyceride concentrations reached the plateau after seven hours fasting in women 
and after eight hours in men. We calculated conversion factors for transforming non-
fasting triglyceride concentrations to the fasting values. The conversion factors were 
slightly diverse in different subgroups: the factor was -2.3 % per hour in low 
triglyceride concentrations compared to the -6.5 % in subjects whose BMI was >35 
kg/m2. There was a consistent difference of 0.4 mmol/l in triglyceride concentrations 
between men and women. This sex difference should be taken into account when 
defining reference intervals and target values in the national guidelines.  
The prevalences of high LDL-C and metabolic syndrome were calculated with 
the original non-fasting triglyceride values, with corrected values, and with true-
fasting values. Non-fasting triglyceride concentrations resulted in a 5.1 % 
misclassification of patients having LDL-C higher than 3.00 mmol/l. Although 
triglycerides compose only a minor factor, when calculating LDL-C concentration 
by Fridewald formula, too high triglyceride concentration has an effect to the final 
LDL-C concentration. After correction the proportion of misclassified subjects 
decreased to 1.6 % compared to the true-fasting subjects. In the population level this 
means that some tens of thousands more subjects have increased risk for CVD. The 
prevalences for metabolic syndrome proved to be more comparable with true-fasting 
subjects after corrected the non-fasting triglyceride concentrations to true-fasting 
values: the difference between prevalences decreased from 4.2 % to 2.1 %. Using 
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the true-fasting triglyceride concentrations instead of non-fasting ones is 
physiologically relevant, when comparing prevalences for metabolic syndrome. 
6.4 Reference intervals for apoA-I, apoB, and apo B/apoA-I 
ratio 
Reference intervals for apoA-I, apoB and apoB/apoA-I ratio were calculated from 
the FINRISK 2007 study. The population sample was stratified according to age and 
sex, making it suitable for determining reference intervals. The healthy reference 
group was selected by excluding subjects who had obesity, self-reported CVD, 
hypertension, or diabetes. Women had higher apoA-I concentration than men in all 
age groups, but women gained men’s apoB levels in the oldest age group of 65-75. 
The former reference intervals from the Finnish population were from 1990s (Leino 
et al. 1995) demonstrating lower apoA-I and higher apoB concentrations than our 
data. However, sex- and age-spesific differences were quite similar in both studies.  
A Swedish and  a US population sample (NHANES III) showed on average 11 % 
lower mean values for apoA-I  and 40 % higher for apoB when compared to our 
Finnish apoA-I and apoB values (Jungner et al. 1998, Bachorik et al. 1997). The 
subjects for the Swedish study were collected from the general healthcare without 
any exclusion of subjects, which may have affected the apoA-I and apoB 
concentrations. The subjects in NHANES III were a noninstitutionalized civilian 
population. In the Framinghan Offspring Study the mean values for apoA-I (Contois 
et al. 1996a) and apoB (Contois et al. 1996b) in both sexes were similar with the 
Swedish study. The cut-off value of 1.2 g/l for low apoA-I was selected from the 
Framingham Offspring Study according to the 25th percentile value, which 
coincided with the HDL-C concentration 0.9 mmol/l in men. For women the same 
25th percentile showed an apoA-I concentration of 1.34 g/l. However, the same cut-
off value of 1.2 g/l for apoA-I was suggested for both men and women. Based on 
data in this thesis, cut-off values 1.2g/l for men and 1.4 g/l for women were selected. 
Because of the evident sex-difference between apoA-I concentrations, women 
having more than 10 % higher concentrations, the same cuf-off values for both sexes 
underestimate the risk in women.  
The cut-off value for apoB was selected to be equivalent to the LDL-C cut-off 
values. In the Framingham Offspring Study the high risk cut-off value for LDL-C 
was 1.60 g/l (4.1 mmol/l), which was the 75th percentile in men. The corresponding 
apoB concentration was 1.2 g/l. In Finland the cut-off value for LDL-C is 3.0 
mmol/l, which was close to the 50th percentile in the FINRISK 2007 study (Graham 
et al. 2007).  According to this data, the same cut-off value of 0.9 g/l was chosen for 
apoB in men and in women  
The apoB/apoA-I ratio estimates the balance between atherogenic and 
antiatherogenic particles in the circulation. This ratio has turned out to be a better 
risk indicator for CVD than traditional cholesterol, LDL-C, HDL-C, and lipid ratios 
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(Walldius and Jungner 2006). The data from the AMORIS study and the 
INTERHEART study resulted in an increased risk for CVD with an apoB/apoA-I 
ratio of 0.6 for women and 0.7 for men (Walldius et al. 2001, Yusuf et al. 2004). In 
our data these apoB/apoA-I ratios coincided with the 75th percentile. 
6.5 Method comparisons of two homogeneous HDL-C 
methods and two apoA-I methods 
Since homogeneous HDL-C methods had been introduced to the clinical practice in 
1990s, their specifity regarding abnormal lipoproteins has been challenged. Recently 
Miller et al. reported that homogeneous HDL-C and LDL-C measurements are 
nonspecific, when analysing samples from patients with CVD or other dyslipidemias 
(Miller et al. 2010). Our experiences from EQA programs have indicated that 
different manufacturers’ asssay systems occasionally produce enormously different 
HDL-C concentrations. To find out the actual situation in the clinical practice, we 
chose two methods demonstrating the largest discordance in the Finnish EQA 
program: PEG-method and ASD-method. This study was carried out in the 
occupational health care with fresh serum samples.  
The results demonstrated the same phenomenon, which had been seen with some 
EQA samples: PEG-method produced on average 12 % lower results when HDL-C 
concentrations were <1.0 mmol/l and 9 % higher results when HDL-C was >1.55 
mmol/l when compared to ASD-method. This concentration-dependent difference is 
almost impossible to correct with calibration, because the difference varies from 
negative to positive with increasing HDL-C concentration. The cut-off value for low 
HDL-C used in Finland is 1.0 mmol/l, so depending on the method used in the 
laboratory, patients may either be in the increased risk or low risk for CVD. 
According to Kappa statistic, agreement between these two homogeneous methods 
was only slight in women near the HDL-C cut-off value of 1.0 mmol/l. ApoA-I 
concentrations were also measured from the subjects and they showed better 
agreement in both sexes compared to the HDL-C measurements.  
The basic principle in measuring cholesterol content in different lipoprotein 
particles has been to separate apoB-containing, non-HDL lipoproteins from the 
high-density lipoproteins (Warnick et al. 2001). The new innovation of using 
sulphated α-cyclo dextrin together with Mg2+ was discovered to selectively block 
but not precipitate chylomicrons and VLDL particles (Sugiuchi et al. 1995). This 
method used also PEG-modified enzymes, whose selectivity toward HDL-C was 
increased leaving LDL-C non-reacting. The increased β-VLDL in type III 
hyperlipoproteinemia overestimates HDL-C concentrations in PEG-method, because 
the PEG-modified enzymes apparently react with the cholesterol in VLDL particles 
(Lackner and Schmitz 1998). The other article reported in contrast that 
underestimation of HDL-C concentrations with PEG-method may occure when 
analysing samples from type III hyperlipoproteinemic patients (Roberts et al. 2000).  
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The mechanism behind the selectivity of PEG-modified enzymes is not clear, but 
the enzymes might recognise differences in lipoprotein particle density, net charge, 
or size (Sugiuchi et al. 1995). Increased number of sd-LDL particles in 
hyperbetalipoproteinemia may be one of the explanations to these discrepancies, 
because the change of particle size in turn can change the net charge of particles 
more negative (Prassl and Laggner 2008). The ASD-method is based on accelerating 
the reaction of cholesterol oxidase with cholesterol in non-HDL particles. The main 
principles to separate particles by this method have not been published in details, 
however, the bias between CDC’s reference method has been narrower than with 
PEG-method in our laboratory. 
Data in this thesis showed that differences between the HDL-C methods existed 
also when analysing apparently healthy subjects, so it is possible to misclassify 
people in the risk assessment for CVD in clinical practice. These differences in 
HDL-C measurements affect also the calculated non-HDL-C and LDL-C by the 
Friedewald formula. One suggested solution to resolve this problem has been to 
proceed to apolipoprotein measurements, which are better stardardized than direct 
HDL-C and LDL-C methods and in addition, do not need fasting samples (Contois 
et al. 2011, Sniderman et al. 2011). 
6.6 Lipids, lipoproteins, and apoA-I and apoB in different 
pathophysiological conditions  
The changes in lifestyle have increased the prevalences in obesity, MetS and type 2 
diabetes, which demonstrate different lipoprotein distributions from traditional 
cardiovascular diseases. Total cholesterol, triglycerides, and HDL-C measurements 
and calculated LDL-C are not enough anymore for accurate CVD risk assessment. 
Direct HDL-C and LDL-C measurements are not the best methods to estimate the 
numbers of HDL and LDL particles in serum, because of different cholesterol 
content in lipoprotein subpopulations. Occurrence of sd-LDL particles in obesity, 
MetS, and type 2 diabetes results in normal or even low LDL-C concentrations that 
may lead to misclassifications of these subjects.  
In this thesis the healthy reference group from FINRISK 2007 study was 
compared with the different disease groups from the same study. Men with CVD, 
hypertension, diabetes, or obesity had lower total and LDL cholesterol compared to 
the reference group, and the mean apoB concentration was increased only in obese 
subjects. Women with CVD and diabetes had also lower total and LDL cholesterol 
compared to the reference group, but contrary to men, they had simultaneously 
higher apoB concentrations. In fact, women had higher apoB concentrations in all 
disease groups compared to the healthy reference group.  
The nutritional recommendations for cardiovascular disease, type 2 diabetes, and 
MetS have emphasized reducing fat, especially saturated fat, in the diet (Catapano et 
al. 2011). However, a low-fat diet together with a high amount of carbohydrates 
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increases the atherogenic dyslipidemia: increased triglycerides, decreased HDL-C, 
and increased apoB-containing lipoproteins, especially sd-LDL (Parks and 
Hellerstein 2000, Siri-Tarino et al. 2010).  High sugar consumption also may have 
association to type 2 diabetes and other metabolic disorders (Sonestedt et al. 2012). 
In addition to excess amount of free fatty acids, excess carbohydrates, especially 
fructose, increase the VLDL production in the liver (Zammit et al. 2001).  On the 
other hand, increasing the amount of polyunsaturated fatty acids (PUFA) in the diet 
is associated with increased susceptibility of LDL particles to oxidation, which 
makes them more atherogenic (Reaven and Witztum 1996). Sd-LDL particles 
penetrate more easily the arterial wall and are oxidized as well as aggregated, which 
increase the formation of cholesterol-containing macrophages in the subendothelial 
space (Rizzo and Berneis 2007). Carbohydrate restriction in the diet has been shown 
to improve the atherogenic lipoprotein profile and symptoms of MetS and diabetes 
(Volek and Feinman 2005, Volek et al. 2008, Feinman and Volek 2008).  
The amount of low-density lipoprotein particles in the blood circulation instead 
of their cholesterol content is suggested to be more relevant to the risk evaluation for 
CVD in many studies (Sniderman et al. 2011). The total number of atherogenic 
particles includes chylomicron remnants, VLDL, VLDL remnants, IDL, LDL, and 
Lp(a), which all contain apoB. Sniderman et al. reported recently results from a 
meta-analysis, which indicated that apoB was superior to non-HDL-C and LDL-C as 
a predictor of cardiovascular risk (Sniderman et al. 2011). According to their 
calculations the use of apoB as a risk marker could prevent 800 000 more events 
than the use of LDL-C in the US population during a 10-year period.  
Some studies have shown that apoB or apoB/apoA-I ratio are better in the CVD 
risk assessment (Walldius et al. 2001, Yusuf et al. 2004), but there are also studies, 
for example the EPIC-Norfolk study, where no difference compared to the 
traditional lipids was observed (van der Steeg et al. 2007). However, the cohort of 
EPIC-Norfolk study was comprised of apparently healthy people and only few 
diabetic subjects. The data from the Women’s Health Study and Framingham 
Offspring Study found also no evidence for replacing standard lipid measurements 
with apolipoprotein measurements in the primary risk screening (Ridker et al. 2005, 
Ingelsson et al. 2007).   
A case-control study among myocardial infarction (MI) patients reported that 
apolipoprotein ratios were more informative regarding the MI risk than LDL-C or 
HDL-C, but direct measurements of specific lipoprotein subpopulations may be 
even more informative (Parish et al. 2009). The Emerging Risk Factors 
Collaboration concluded that the risk assessment of vascular diseases could be 
simplified by measuring total cholesterol and HDL-C or apoA-I and apoB without 
fasting and avoiding thus possible interferences from triglycerides (Emerging Risk 
Factors Collaboration et al. 2009).  
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6.7 Laboratory diagnostics of dyslipidemia 
NCEP ATP established in 1988 that LDL-C was the principle target in the treatment 
of CVD. Since then homogeneous methods first to measure HDL-C and later LDL-
C were developed. The secondary treatment goal for subjects with 
hypertriglyceridemia has been non-HDL-C. Total cholesterol and triglyceride 
measurements have been reasonably accurate during the decades, but the separation 
of different lipoprotein fractions has been challenging. Homogeneous HDL-C and 
LDL-C measurements separate lipoprotein fractions based on divergent mechanisms, 
which are not clear even to the reagent developers themselves (Sugiuchi et al. 1995). 
ApoA-I and apoB as the main proteins in HDL and LDL particles would be the 
obvious solution to this problem, but many arguments against them have been 
expressed (Boekholdt et al. 2012).  
One of the counterclaims has been that the National Cholesterol Education 
Program Adult Treatment Panel is using the word “cholesterol” in the title of the 
guidelines. However, the European guidelines are titled as “cardiovascular disease 
prevention in clinical practice” and in Finland the guideline is for “treatment of 
dyslipidemia”. Because cholesterol in the circulation is mainly transported in the 
LDL particles, measurement of total cholesterol has been an apparently good 
estimate of atherogenic particles and the risk for CVD in the population level 
(Vartiainen et al. 2000). Measurement of serum total cholesterol, however, does not 
tell how cholesterol is divided between different lipoprotein fractions: atherogenic 
and antiatherogenic. The next effort to improve risk assessment for CVD has been to 
measure the cholesterol content in HDL and LDL particles, but these measurements 
have been proven to be nonspecific especially for atypical lipoprotein particles 
during different dyslipidemic states (Miller et al. 2010).  
The major question has arisen: what is the best marker for increased risk for 
atherosclerosis: LDL-C, non-HDL-C, or apoB? LDL-C measures the amount of 
cholesterol in low-density lipoprotein particles, non-HDL-C consists of the 
cholesterol in all potentially atherogenic particles and apoB is an estimate of the 
number of atherogenic particles (Grundy 2002, Sniderman 2002, Contois et al. 
2009). Direct LDL-C methods should ideally separate the relevant LDL particles for 
the cholesterol measurement and if calculated by the Friedewald formula, HDL-C 
methods should measure the cholesterol only from the circulating HDL particles. 
This could have been successful once lipoprotein particles comprised homogeneous 
population of particles with equal characteristics like size and charge. However, the 
size, charge, lipid and apolipoprotein compositions of lipoproteins vary according to 
the metabolic status (Rizzo and Berneis 2007). Non-HDL-C has been suggested to 
be an estimate of apoB particles especially in hypertriglyceridemia. However, non-
HDL-C and apoB are not equal and can lead to different CVD risk assessment 
(Sniderman et al. 2010).  
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The recommendations for the diagnosis and treatment of dyslipidemia and 
prevention of CVD by the Canadian Cardiovascular Society are one of the first 
guidelines to include apoB to the risk assessment (McPherson et al. 2006). The 
American Diabetes Association and the American College of Cardiology 
Foundation suggested using apoB measurements for patients with cardiometabolic 
risk during statin therapy in addition to LDL-C and non-HDL-C measurements 
(Brunzell et al. 2008). The American Accociation for Clinical Chemistry has given a 
position statement to implement apoB measurement together with LDL-C to the 
NCEP ATP III guidelines in the US (Contois et al. 2009). 
The flow chart in Figure 17 demonstrates the proposed laboratory measurements 
to diagnose dyslipidemia. Because patients with obesity, MetS, and type 2 diabetes 
may have an increased number of atherogenic particles in the circulation, the apoA-I 
and apoB measurements should be included to the basic screening tests for 
dyslipidemia (Marcovina and Packard 2006). Also if the triglyceride concentration 
is >1.7 mmol/l or HDL-C concentration is <1.0 mmol/l in men or <1.2 mmol/l in 
women, apoA-I and apoB concentrations should be measured after the screening 
tests: total cholesterol, HDL-C, triglycerides and LDL-C. 
Table 24 shows the suggested therapeutic target goals for low risk subjects. For 
higher risk patients the target goals for LDL-C and apoB should be lower. The 
NCEP ATP III guidelines have suggested the target LDL-C concentration as low as 
1.8 mmol/l for the highest risk patients (Grundy et al. 2004), which is equivalent 
with an apoB concentration of 0.6 g/l. Because non-HDL-C is based on the HDL-C 
measurement, the differences between direct HDL-C methods may have an impact 
on the accuracy of non-HDL-C concentration and as a consequence to the risk 
assessment. In this context the direct measurement of apoB is a superior estimate of 
the atherogenic particles in the circulation (Barter et al. 2006, Sniderman et al. 
2011). HDL-C and apoA-I concentrations are higher in women than in men, thus 
this sex-difference should be taken into account also in target goals for dyslipidemia. 
As with apoB, also apoA-I is a better estimate for antiatherogenic HDL particles 
than the HDL-C concentration, which may vary according to the method. ApoA-I 
and apoB measurements do not need fasting before blood sampling, and non-fasting 
triglycerides could be an even better measurement for the CVD risk assessment 
(Nordestgaard et al. 2007, Langsted et al. 2008). 
In the future, the analyses of different HDL and LDL subpopulations might 
produce even more specific information of these particles’ atherogenic or 
antiatherogenic properties. However, substituting apoA-I and apoB measurements 
for direct HDL-C and LDL-C methods could be a proper step forward to more 
accurate CVD risk assessment. 
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Figure 17. Proposed chart of laboratory diagnostics for dyslipidemia based on the 
 data in this thesis. 
Table 24. Suggested treatment goals for lipids, lipoproteins, and apolipoproteins for 
 low risk subjects based on the European guidelines (Graham et al. 2007) 
 and data in this thesis. 
Measurement  Men Women 
Total cholesterol, mmol/l <5.0 <5.0 
LDL-C, mmol/l <3.0 <3.0 
Triglycerides, mmol/l <1.7 <1.7 
HDL-C, mmol/l >1.0 >1.2 
ApoA-I, g/l >1.2 >1.4 
ApoB, g/l <0.9 <0.9 
ApoB/apoA-I <0.7 <0.6 
 
Total cholesterol 
Triglycerides 
HDL-C 
LDL-C 
ApoA-I + apoB 
in obesity, MetS,  
and type 2 diabetes + 
If triglycerides > 1.7 mmol/l 
or HDL-C < 1.0 mmol/l in men and 
< 1.2 mmol/l in women 
  
 ApoA-I + apoB 
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7 Conclusions 
Most of the serum cholesterol is transported as a cargo inside low-density 
lipoproteins. Because proportion of low-density lipoproteins is about 70 % of 
circulating lipoproteins, total cholesterol and LDL-C measurements have been good 
estimates for the amount of atherogenic particles in the circulation. However, LDL 
particle number is more critical in the genesis of atherosclerosis than their 
cholesterol content. Obesity, MetS, and type 2 diabetes appear commonly with 
normal or even decreased total cholesterol and LDL-C, but increased numbers of 
triglyceride-rich lipoproteins and sd-LDL, and decreased HDL-C. ApoB 
incorporates all atherogenic lipoproteins from chylomicron remnants to LDL 
particles, which all can participate in the genesis and progression of atherosclerosis. 
Cholesterol-lowering should not be the main aim of CVD prevention anymore, but 
lowering the number of atherogenic particles as well as increasing those HDL 
subpopulations that really display protection. 
 
Major conclusions of this thesis are as follows: 
 
• Participating in the external quality assessment programs with target values 
measured by reference methods is essential, when interpreting the effects of 
the systematic errors on the population trends. 
 
• Transforming non-fasting triglyceride concentrations to fasting values has 
minor, although significant effect on the prevalences in high LDL-C and 
MetS. 
 
• Two homogeneous HDL-C methods demonstrated concentration-dependent 
differences in HDL-C concentrations, which may cause misclassification of 
subjects in the risk assessment of cardiovascular disease. 
 
• ApoB measurements produce more specific information for the risk 
evaluation of CVD, especially in obesity, MetS, and type 2 diabetes as 
compared to total cholesterol and LDL-C measurements. 
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